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ABSTRACT 
 
FLOR DE MARIA EVANGELISTA MONTOYA: Pathogenicity and Epitope Specificity of 
IgG4 autoantibodies in Endemic Pemphigus Foliaceus 
(Under the direction of Dr. Zhi Liu) 
 
 Endemic pemphigus foliaceus, also known as Fogo Selvagem (FS), is an autoimmune 
blistering skin disease that exhibits geographic clustering and 100% mortality without 
treatment. An active focus of FS is located in the rural reservation of Limao Verde (LV), 
Mato Grosso do Sul, Brazil. It is widely accepted that the autoantibodies that mediate FS are 
predominantly of the IgG4 subclass against Desmoglein 1 (Dsg1) and that healthy 
individuals living in LV posses a mixture of circulating IgG anti-Dsg1 autoantibodies. It has 
been suggested that an unknown environmental trigger present in LV may induce an anti-
Dsg1 autoimmune response, which in certain genetically predisposed individuals leads to a 
pathogenic IgG4 response and clinical disease. The transition from preclinical to clinical 
disease in FS has been associated with subclass switching and epitope spreading within the 
extracellular domain of Dsg1. 
 The N-terminal region of Dsg1 has been reported to be the target for pathogenic FS 
IgG autoantibodies. However, the fine epitope specificity for FS IgG4 autoantibodies 
remains unknown. The work in this dissertation refines the identification of epitopes in Dsg1 
that are recognized specifically by IgG4 autoantibodies from FS patients. Two dominant 
conformational epitopes were identified using epitope excision and MALDI-MS/MS. One 
epitope was located within the EC1 domain of Dsg1 (A129-R144) and the second epitope in 
 iv 
the EC2 domain (Q201-R213). Moreover, residues M133 and Q135 are required to achieve 
the proper conformation of the epitope recognized by pathogenic IgG4 autoantibodies in FS. 
 This study also reports that IgG4 FS antibodies recognize LJM11, a protein found in 
the saliva of Lutzomya longipalpis. In addition, mice immunized with LJM11 generate anti-
Dsg1 antibodies. Thus, insect bites may deliver salivary antigens that initiate a cross-reactive 
IgG4 autoimmune response in genetically susceptible individuals, which subsequently leads 
to development of FS. 
 The findings of this dissertation may uncover targets such as the epitope in EC1 for 
the development of epitope-specific preventative and therapeutic strategies. Additionally, this 
work identifies an environmental, non-infectious antigen, which may trigger development of 
potentially pathogenic autoantibodies in autoimmune disease. 
 
 
 
 
 
 
 
 
 
 v 
This dissertation is dedicated to my husband Kevin, for his unconditional love, support and 
for being a blessing in my life. To my mother Pilar and to the memory of my father Félix, for 
all their love and for providing me with the support to get to this moment. To my brother 
Félix for all his love, for being my inspiration to pursue an intellectual career, and for taking 
care of our mother during my “adventure” away from home. 
 
 
“How will I pay the Lord for all the good He has done for me?” 
(Psalm 116,12) 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
ACKNOWLEDGEMENTS 
 I would like to thank my advisor Dr Zhi Liu for the opportunity to work in his lab as 
well as for his guidance and support during graduate school. I have learned from him how to 
be an independent scientist, as well as how to balance a successful career and family. I also 
thank him for accommodating and supporting me during stressful and challenging times in 
my life outside of the lab. 
 I am thankful to the current and past members of the Liu Lab, it has been great to 
work with you all. Most especial way to my graduate school “sister” Dr. Lisa Heimbach, who 
has being a wonderful friend and listener, especially when things got challenging for our 
projects and we thought we would “graduate in 10 years”.  I am deeply grateful to Lisa for 
her scientific and technical advice and for her help outside the lab, especially when I had 
surgery and the times she took care of “Bubu”. I would also like to thank Kayla Shumate, 
who has been extremely helpful during my last semester in the lab. Kayla is a great friend 
and lab manager. Thanks to Lin, Bin-Jin, Peng, Jaime, Megan, Ying-Ching and Lan for their 
help, friendship and for making the lab a fun place to work. I will miss you all. 
 I am deeply thankful to the UNC Dermatology Department, for being my “home” 
before and during graduate school. Especially to the chairman, Dr Luis A. Diaz, who 
introduced me to the life of a researcher in US and has been a wonderful mentor throughout 
my scientific training at UNC. I am grateful to him for his constant advice for my scientific, 
personal and career goals. Dr Diaz has been more than supportive of my training to become 
the scientist I am now. I am also grateful to Drs. Donna Culton and Ye Qian, for their 
 vii 
scientific advice and precious friendship, they always had a smile for me during hard times 
the lab and reminded me to breathe and keep going.  I am also thankful to Dr Ning Li, 
Phillip, Paula, Joseph, Aileen, Marilia, Melanie, Cindy and all the Dermatology family, for 
all their help, ideas and friendship. 
 I would like to thank my dear thesis committee: Drs. Stephen Clarke, Stefanie 
Sarantopoulos, Barbara Vilen and Luis Diaz. They have been amazingly supportive in the 
preparation of my dissertation. I appreciate their constant availability to answer my questions 
and discuss my research during single conversations or committee meetings. I am thankful 
for all their questions, by which they were teaching me how to think and be a better scientist. 
I am also thankful to our collaborators, Drs. Aleeza Roth, David Klapper and Bahjat Qaqish, 
for their scientific expertise and technical contributions that were key for the completion of 
my dissertation. 
 I would like to acknowledge other mentors and friends from the Microbiology and 
Immunology Department, especially Dixie Flannery, who is an amazing Student Services 
Manager, she guided me in every step, form, requirement I had to fulfill during graduate 
school, she became my friend and second “mother” who was always checking how my 
graduate school and personal life was going. Drs. Marcia Hobbs, Lorraine Cramer, Laura 
White, Roland Tisch, Glenn Matsushima and Silva Markovic-Plese were key resources for 
my doctoral training and I am grateful for their wise advice and precious time.  
 Finally, I want to recognize the memory of Dr. Angel Quintanilla, my former mentor 
in Peru, who shared with me his enthusiasm for research and discovery. He believed in me on 
every step I took to become a scientist. Also, to my parents in-law and the wonderful friends 
I met at the Newman Center, I am grateful for their support, encouragement and prayers.  
 viii 
TABLE OF CONTENTS 
LIST OF TABLES  …………………………………………………………………….......... x 
LIST OF FIGURES  …………………………………………………………………....…... xi 
LIST OF ABBREVIATIONS …………………………………………………................... xii 
Chapter 
I. INTRODUCTION………………………………………………………….. 1 
1.1. PEMPHIGUS.…………………………………………………………… 1 
1.2. INTERCELLULAR JUNCTIONS AND THE CADHERINS ……......... 2    
  1.3. THE PEMPHIGUS GROUP: Clinical Manifestations  
        and Desmosomal Targets ……….……………………...……………….. 8 
 1.4. IMMUNOPATHOGENESIS OF AUTOANTIBODY-INDUCED  
        BLISTERING IN PEMPHIGUS ………………………..…………….. 10 
 1.5. ENVIRONMENTAL FACTORS IN ENDEMIC PEMPHIGUS 
         FOLIACEUS ………………………………………………………….. 14 
 1.6. ANIMAL MODELS IN FS .……………………......………................. 16 
 1.7. CONCLUDING REMARKS ………….…………......……………...... 16 
 REFERENCES ……………………………………………………….......... 18 
II. DISSECTING THE CONFORMATIONAL EPITOPES   
RECOGNIZED BY PATHOGENIC IgG4  
 ANTI-DESMOGLEIN 1 AUTOANTIBODIES IN  
 ENDEMIC PEMPHIGUS FOLIACEUS  …...................……………….. 30 
 2.1. INTRODUCTION ………………………………………...................... 30 
 2.2. MATERIAL AND METHODS ……………………………………...... 32 
 
 ix 
 2.3. RESULTS ……………………………...…………………………….... 40 
 2.4. DISCUSSION …………………………………………………………. 54 
 REFERENCES ……….......………………………………………………... 59 
III. INDUCTION OF IgG4 ANTI-DESMOGLEIN 1 ANTIBODIES  
 BY HEMATOPHAGUS INSECTS BITES .…………………………...... 63 
 3.1. INTRODUCTION ………………...…………………………............... 63 
 3.2. MATERIAL AND METHODS………………………………………... 64 
 3.3. RESULTS ……………………………………………………………... 67 
 3.4.  DISCUSSION ……………...…………………………………………. 74 
 REFERENCES …………...………………………………………….......… 76 
IV. SUMMARY AND FUTURE DIRECTIONS …….…………................... 79 
 REFERENCES .............................................................................................. 86 
 
 
 
 
 
 
 
 
 
 
 
 x 
LIST OF TABLES 
 
Table 
 2.1. Primers used for construction of swapped-domain recombinant proteins and  
        site directed mutagenesis ……………………....……………………………..   35 
 2.2. Conformational epitopes in the extracellular domain of human Dsg1 targeted  
        by  IgG4 autoantibodies from 20 FS patients …………………………….......   46 
 
 2.3. Frequency of IgG4 anti-Dsg1 autoantibodies targeting conformational  
        epitopes identified by MALDI-MS/MS analysis ………………….………….   47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
LIST OF FIGURES 
Figure 1.1. :  Molecular components of intercellular junctions and pemphigus variants ........ 4    
Figure 2.1. : Domain swapped hDsg1/Dsc1 recombinant proteins produced in  
          baculovirus expression system …...................................................................... 41 
Figure 2.2. : Analysis of IgG4 and non-IgG4 autoantibodies from FS patient serum by IP  
         and passive transfer …………………………………………………................ 42 
Figure 2.3. : Prevalence of IgG4 autoantibodies against Dsg1(EC1) by ELISA ……........... 43 
Figure 2.4. : Epitope mapping by epitope excision and mass spectrometry ……………...... 44 
Figure 2.5. : Location of 2 conformational epitopes recognized by FS IgG4  
         autoantibodies in  a predicted model of hDsg1 extracellular domain ……........ 48 
 
Figure 2.6. : Site directed mutagenesis in the extracellular domains of hDsg1 and hDsg4.... 51 
Figure 2.7. : Mutation of residues M133 and Q135 in EC1 domain of Dsg1 dramatically 
          reduces the binding of IgG4 autoantibodies to Dsg1 extracellular domain........ 52 
 
Figure 2.8. : Detection of IgG4 autoantibodies against Dsg4-WT and Dsg4-mutants by  
         ELISA…………................................................................................................. 53 
 
Figure 3.1. :  FS patients have high levels of anti-SGLL IgG4 antibodies ……………….... 68 
Figure 3.2. : The cross-reactivity of two IgG4 anti-Dsg1 monoclonal antibodies from FS  
          to SGLL by ELISA …………………………………………………………... 69 
Figure 3.3. : IgG4 antibodies from FS patients and two IgG4 monoclonal anti-Dsg1  
          antibodies derived from FS patients recognize LJM11, a protein  
          component from SGLL ……………………………………………………..... 71 
Figure 3.4. : FS autoantibodies recognize LJM11 and sera from mice immunized with  
         LJM11 bind human Dsg1 ……………………………………………………... 73 
 
Figure 4.1. : A working model for FS immunopathogenesis ……………………………..... 81 
 
  
 
 
 xii 
LIST OF ABREVIATIONS 
 
AFM  atomic force microscopy 
Anti-HA anti-influenza hemagglutinin antibody 
Anti-His anti-histidine antibody  
A129  alanine at position 129 
A130  alanine at position 130 
Bcl-2  B-cell lymphoma 2 
BSA  bovine serum albumin 
CaCl2  calcium chloride 
CAR  cell-adhesion recognition site 
cDNA  complementary Deoxyribonucleic acid 
CH1  constant domain 1 
CNBr  cyanogen bromide 
DEAE  diethylaminoethyl cellusose 
DP  desmoplakin 
Dsc  desmocollin 
Dsg  desmoglein 
EC  extracellular domain 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
EM  electron microscopy 
F(ab)  fragment (antigen binding) 
 xiii 
FAT  phenylalanine, alanine, threonine 
FBS  fetal bovine serum 
Fc  fragment crystallizable region 
FS  Fogo Selvagem (endemic pemphigus foliaceus) 
GST tag glutathione S-transferase tag 
HAV  histidine, alanine, valine 
HC  human control 
hDsg1  human desmoglein 1 
hIgG4  human immunoglobulin class G subclass 4 
His-tag histidine-tag 
HLA  human leukocyte antigen 
HRP  horseradish peroxidase 
HSP  heat shock protein 
IB  immunoblot 
IEN  intraepidermal neutrophilic 
IgA  immunoglobulin class A 
IgG  immunoglubulin class G 
IgG4  immunoglobulin class G subclass 4 
IP  immunoprecipitation 
IRB  Institutional Review Boards 
kD  kilodalton 
LV  Limao Verde (rural reservation in Brazil) 
MALDI-TOF/TOF MS/MS matrix-assisted laser desorption ionization time of flight mass  
    spectrometry 
 xiv 
 
MALDI-MS/MS  short version of MALDI-TOF/TOF MS/MS 
MAPK  mitogen-activated protein kinase 
MEC  mutated extracellular domain  
mPV  mucosal Pemphigus Vulgaris 
mcPV  mucocutaneous Pemphigus Vulgaris 
µg  microgram 
µL  microliter 
mM  millimolar 
M133  methionine at position 133 
NCBI  National Center for Biotechnology Information 
ng  nanogram 
NHS  normal human serum 
NIAID  National Institute of Allergy and Infectious Diseases 
Ni-NTA nickel-nitriloacetic acid 
O.D.  optical density 
PBS  phosphate buffered saline 
PCR  polymerase Chain Reaction 
PF  pemphigus foliaceus 
PG  plakoglobin 
PKP  plakophilin 
PNP  paraneoplastic pemphigus 
PV  pemphigus vulgaris 
Q135  glutamine at position 135 
 xv 
Q201  glutamine at position 201 
RAL  arginine, alanine, leucine 
ROC  receiver-operating-characteristic analysis 
RT  room temperature 
R144  arginine at position 144 
R213  arginine at position 213 
scFv  single-chain variable fragment 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SFM  serum-free medium 
SGLL  salivary gland from Lutzomyia longipalpis 
SPD  subcorneal pustular dermatosis 
TBS  tris buffered saline 
TFA  trifluoroacetic acid 
TPCK  L-1-tosylamido-2-phenylethyl chloromethyl ketone 
UNC  University of North Carolina at Chapel Hill 
US  United States 
VHH  heavy-chain single variable domain antibody 
WT  wild type 
W51  tryptophan at position 51 
YAG  yttrium-aluminum garnet 
YAS  tyrosine, alanine, serine 
YAT  tyrosine, alanine, threonine
CHAPTER I 
INTRODUCTION 
 
1.1. PEMPHIGUS 
Pemphigus is a group of rare, autoimmune blistering diseases of the skin and mucous 
membranes mediated by autoantibodies against desmosomal members of the cadherin 
superfamily.  There are several variants of pemphigus, each with unique clinical, histologic, 
and immunologic features. Interestingly, when different desmosomal proteins are targeted by 
the autoimmune response, different clinical and histologic features are seen [1, 2].  
There are two major intercellular junctions that mediate cell-cell adhesion in 
squamous epithelia: desmosomes and adherens junctions. Keratinocytes express 
transmembrane glycoproteins such as desmogleins and desmocollins to form desmosomes, 
whereas E-cadherin forms adherens junctions.  It is widely accepted that the antibodies that 
mediate pemphigus are of the IgG isotype, predominantly of the IgG4 subclass, and are 
directed against the extracellular domain of desmosomal cadherins [3, 4]. Binding of these 
autoantibodies causes loss of epithelial cell adhesion, via a process known as acantholysis, 
which leads to blister formation in the epidermis.  Pemphigus autoantibodies are pathogenic 
when passively transferred into neonatal Balb/c mice, generating blisters at the injection site, 
thus resembling the human disease [5].  The immunological targets for pemphigus 
autoantibodies have been characterized by immunochemical methods such as 
immunoprecipitation and immunoblotting since the 1980s [6, 7]. With the introduction of 
 
 
2 
cloning techniques and cDNA libraries, the isolation of cDNA for pemphigus antigens 
demonstrated that desmogleins are indeed the target antigens in pemphigus. 
 
1.2. INTERCELLULAR JUNCTIONS AND THE CADHERINS:  
 Intercellular junctions in the epidermis allow keratinocytes to adhere to one another 
and maintain the integrity of the epithelium.  Morphological and biochemical studies have 
defined two major types of intercellular junctions in epithelial cells: adherens junctions and 
desmosomes [8, 9]. These intercellular junctions are composed of cadherins, a superfamily of 
calcium-dependent adherent proteins, which play an important role in the dynamic regulation 
of intercellular adhesion [10]. The cadherin superfamily is characterized by multiple 
“cadherin repeat” sequences of about 110 aminoacids in their extracellular domains (EC) and 
comprised of two major groups: Classical cadherins (E-, P-, N-cadherin) and desmosomal 
cadherins (desmogleins and desmocollins).  
 Classical cadherins are expressed in the adherens junctions and share high structural 
and sequence homology with the extracellular domains of desmosomal cadherins that are 
expressed in the desmosomes.  All cadherins are type 1 transmembrane glycoproteins 
presenting 5 tandem cadherin repeats (EC1 to EC5) of about 110 aminoacids containing 
calcium–binding sites and a cell-adhesion recognition (CAR) site in their extracellular 
domains [11-13]. The CAR site is a tripeptide motif located within EC1 (the most amino-
terminal repeat).  In classical cadherins, this motif is HAV (histidine, alanine, valine), 
whereas in desmosomal cadherins the motif may be RAL (arginine, alanine, leucine), YAT 
(tyrosine, alanine, threonine), FAT (phenylalanine, alanine, threonine) or YAS (tyrosine, 
alanine, serine) [14]. Classical cadherins are ultimately linked to the actin cytoskeleton via 
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!- and "-catenin [15, 16], and desmosomal cadherins are linked to the intermediate keratin 
filaments through plakoglobin and desmoplakins I and II [9, 17]. 
 E-cadherin and P-cadherin are classical cadherins expressed in the epidermis. E-
cadherin is expressed in all layers of the epidermis, whereas P-cadherin is limited to the basal 
cell layer [18]. 
 
THE DESMOSOME: 
 The first observation of the desmosome was made by the Italian pathologist Giulio 
Bizzozero (1864).  He observed them as small, dense nodules and called them “nodes of 
Bizzozero”.  The term desmosome emerged later with Joseph Shaffer in 1920, from the 
Greek words “desmo” (bond) and “soma” (body) [19]. In the subsequent years, techniques 
such as electron microscopy (EM), have revealed the complex structure and organization of 
the desmosomes. The desmosome consists of two morphologically identifiable zones: the 
extracellular core region (desmosomal core) and the intracellular dense plaque region 
(desmosomal plaque).  With the introduction of techniques such as genetic cloning and 
immunohistochemistry, the components of the desmosome have been cloned, their 
organization within the organelle has been mapped, and their ability to interact with one 
another has been defined [20]. As shown in Fig. 1, there are three major components in the 
desmosome : a) desmosomal cadherins (desmogleins and desmocollins), b) the armadillo 
family members (plakoglobin and plakophilins) and c) the plakin family (desmoplakins).  All 
3 components link to each other, and ultimately to the intermediate keratin filaments, in order 
to maintain cell-cell adhesion. 
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a) Desmosomal cadherins: 
 Desmosomes were originally isolated from cow nose epidermis [21] and chemically 
characterized [22]. High levels of glycosylated proteins were found to be the main 
component of the desmosomes, and they were postulated to mediate cell-cell adhesion [23, 
24]. Antibodies against a particular desmosomal glycoprotein were developed and used to 
screen a cDNA library.  In this manner, the first desmosomal cadherin was cloned, 
sequenced, and named desmoglein derived from the greek “glein” (glue) [25]. Since then, the 
desmosomal cadherins family has been found to consist of seven different proteins: four 
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Figure 1.  Molecular components of intercellular junctions and pemphigus variants. 
Adhesion proteins expressed in the intercellular junctions as targets for pemphigus variants 
are shown. PF=pemphigus foliaceus, FS=Fogo Selvagem, mPV=mucosal pemphigus vulgaris, 
mcPV= mucocutaneous pemphigus vulgaris, PNP=paraneoplastic pemphigus. 
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desmoglein isoforms (Dsg1, Dsg2, Dsg3 and of Dsg4) and three desmocollin isoforms (Dsc1, 
Dsc2 and Dsc3), all encoded by separate genes located on chromosome 18 in humans [26, 
27].  
 Dsg1 and Dsc1 are the major desmosomal cadherins in the skin where they are 
expressed throughout the epidermis, but most prominently in the upper layers. Dsg3 and 
Dsc3 expression is predominant in the lower epidermis and decreased toward the upper 
layers.  Dsg1/Dsg3 and Dsc1/Dsc3 are mostly restricted to stratified epithelial tissues, such 
as the skin.  Dsg2 is expressed in a wide range of other simple epithelial tissues and 
myocardia in the heart, whereas Dsg4 is mostly expressed in hair follicles [28].  
Desmocollins and desmogleins are always found as a pair in the desmosomes; however, the 
precise nature of their interaction is still under debate. Several studies indicate that 
desmosomal cadherins contain a CAR site within their N-terminal EC1 extracellular domain 
and that this site is critical for maintenance of desmosomal adhesion [11]. The CAR site 
sequence for Dsg1 and Dsc1 are RAL and YAT, respectively [13]. Interestingly, peptides 
derived from these sequences were able to block the homophilic adhesion mediated by Dsg1 
and Dsc1 upon incubation [12, 13]. Based on predictions from the C-cadherin crystal 
structure, recent cryo-electron microscopy studies in human epidermis showed cis- and trans- 
interactions of the EC1 domains, possibly via insertion of the tryptophan in position 51 
(W51) into the hydrophobic pocket of the CAR site [29]. However, they also found some cis-
interactions of the EC 4-5 domains and it has been suggested that desmosomal cadherins may 
show periodically zipper-like arrangements similar to classical cadherins [30].  
 It is well known that classical cadherins form homo-dimers in order to mediate 
adhesion. In contrast, several studies indicate that desmosomal cadherins undergo both 
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homophilic and heterophilic trans-interactions.  Using EC1-2 fragments of Dsg2, Dsc2 or 
Dsg3, it was shown that homophilic interactions occur in vitro [31, 32]. In addition, Waschke 
et al. have utilized atomic force microscopy (AFM) to estimate the strength of interaction 
between purified Dsg1 ectodomains [33] and showed that, in fact, Dsg1 could form homo-
dimers and that the molecular binding properties of this homophilic adhesion may be 
comparable to other cadherins. Thus, mutation of key amino acid residues such as tryptophan 
in position 51(W51) and alanine at position 130(A130) that are involved in adhesion 
mediated by classical cadherins, abolished homophilic adhesion of desmosomal cadherins 
[34]. Recent studies using a similar AFM approach have shown Dsc3 homophilic binding 
and heterophilic interaction with Dsg1, but not with Dsg3 [35]. Heterophilic binding of Dsg2 
with Dsc1 or Dsc2 have also been demonstrated [32, 36]. Furthermore, these heterophilic 
interactions also form in a calcium-dependent manner. 
 
b) The armadillo proteins in the desmosome:  
 In the desmosomal plaque, the armadillo proteins plakoglobin and plakophilin 
associate with the cytoplasmic domains of desmosomal cadherins. 
 
-Plakoglobin (PG). Originally defined in the Drosophila homolog Armadillo, PG is also 
called #-catenin and is encoded by a gene in chromosome 17 [37]. Its counterpart is "-
catenin, expressed in adherens junctions.  Similar to "-catenin, PG is characterized by 12 
armadillo (arm) repeats, which are ~ 42 amino acid domains flanked by distinct N- and C- 
terminal domains, which are less structured than the central region and have been suggested 
to affect PG function [38, 39]. The central arm region of PG shares 65% amino acid identity 
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with "-catenin. PG can substitute for "-catenin in adherens junctions because both bind E-
cadherin with similar affinity.  However, PG has higher affinity for desmogleins, which 
explains the exclusion of "-catenin from desmosomes [40]. The arm domain of PG associates 
with both the intracellular domain of desmosomal cadherins and the N-terminus of 
desmoplakin [41-43]. Thus, PG is a critical linker in desmosomal adhesion. 
 
-Plakophilins (PKP). PKP are members of a subfamily of armadillo proteins related to 
p120ctn. Three desmosomal PKPs (1, 2 and 3) have been described, and the genes encoding 
them are located on chromosomes 1, 12 and 11 respectively [44]. PKP1 and PKP2 have 2 
isoforms (“a” and “b”) that result from alternative splicing [45, 46]. There is a fourth 
plakophilin : PKP4, also known as p0071, which is highly related to p120ctn and $-catenin 
[47].  PKPs (1-4) have been shown to bind directly to the intracellular domain of 
desmosomal cadherins.  This interaction is mediated by their amino-terminal head domain 
and the functions for their armadillo repeats remain unknown. PKPs can also bind PG in 
order to facilitate clustering of desmosomal cadherins through lateral stabilizing interactions, 
which increases desmosome strength [41]. 
 
c) The plakins: Another family of proteins responsible for cell-cell adhesion is the plakins, 
which are linkers between the cytoskeleton and cell-cell or cell-matrix interactions [48].  
Desmoplakin (DP) is an essential component of the desmosomal plaque, and is recruited by 
the armadillo proteins in order to link the intermediate filament network with the 
desmosomal junctional complex.  DP is encoded on chromosome 6 and has 2 variants (DP-1 
and DP-2) [49, 50]. The amino-terminal domain of DP binds the other desmosomal plaque 
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proteins (PG and PKP), its central coiled-coil rod domain mediates dimerization, and its 
carboxy-terminal tail is the linker for intermediate filaments [41, 51]. Other members such as 
plectin, envoplakin and periplakin are also found in desmosomes; however, their roles are 
still unclear.  Genetic studies have shown that desmoplakin is the only indispensable plakin 
in intercellular junctions.  Thus, inactivating plectin, which is present in desmosomes and 
hemidesmosomes, did not affect cell-cell adhesion in mice or humans [52, 53]. In addition, 
when using DP-deficient mice, skin blistering was observed and the desmosomes were not 
anchored to the intermediate filaments [54]. 
 
1.3. THE PEMPHIGUS GROUP: Clinical Manifestations and Desmosomal Targets 
 The pemphigus group consists of many disease variants, each with unique clinical, 
histologic, and immunologic features [55]. These disease variants include pemphigus 
vulgaris (PV), pemphigus foliaceus (PF), endemic pemphigus foliaceus (also known as Fogo 
Selvagem: FS), paraneoplastic pemphigus (PNP), and IgA pemphigus.   
 PV is the most common form of the pemphigus group [2], and typically presents with 
erosions limited to the mucosal (oropharyngeal and/or genital) tissue, classified as mucosal 
PV (mPV). In most patients the disease progresses to involve the cornified cutaneous surface 
as well with blisters and/or erosions over the trunk and extremities (classified as 
mucocutaneous PV or mcPV). Histologically, PV exhibits a suprabasilar split with 
acantholysis.  While mPV patients classically harbor autoantibodies to desmoglein 3 (Dsg3) 
alone, mcPV patients show autoantibodies to both Dsg3 and Dsg1 [2, 55-57]. Dsg3 and Dsg1 
affinity purified autoantibodies from mcPV patients are sufficient to induce suprabasilar 
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acantholysis upon passive transfer in a neonatal mouse model of disease (discussed in 
Section 1.6), thereby establishing pathogenicity [58-60]. 
 PF presents clinically with superficial blisters or erosions over the trunk and 
extremities.  In many patients, the blisters rupture spontaneously prior to presentation and the 
clinical exam reveals only superficial crusting and erosions. There is no mucosal 
involvement in PF.  Histologically, PF shows a subcorneal split with acantholysis.  Patients 
with PF classically harbor autoantibodies to Dsg1 alone [2, 55, 56]. Similar to PV, the 
establishment of Dsg1 as the target autoantigen was defined by affinity purified anti-Dsg1 
autoantibodies in the neonatal passive transfer model [61]. 
 FS represents an endemic form of PF with identical clinical, histologic, and 
immunologic features.  The endemic nature of this disease makes it an ideal population to 
study the fine aspects of genetic susceptibility and environmental triggers of autoimmune 
disease [62]. Autoantibodies to Dsg1, particularly those of the IgG4 subclass, are a serologic 
indicator of disease in this patient population [63]. E-cadherin has also been shown to be a 
potential antigenic target in FS [64]. In addition, a recent serological analysis reveals that FS 
patients and many healthy controls living in endemic areas also harbor autoantibodies to 
other Dsg and Dsc family members, in addition to the anti-Dsg1 antibodies previously 
reported [65]. 
 PNP is a very unique pemphigus variant that presents with extensive mucositis and 
polymorphic cutaneous lesions in the clinical setting of malignancy.  Histology of these 
lesions reveals intraepidermal clefting with acantholysis, but also shows a dense lichenoid 
infiltrate with interface dermatitis and necrotic keratinocytes [66, 67]. Patients with PNP 
harbor autoantibodies to Dsg1 and Dsg3, which are thought to be responsible for the 
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acantholysis, as removal of the Dsg3 specific antibodies from PNP sera abrogates the 
pathogenicity in the neonatal passive transfer model [68]. These patients also have 
autoantibodies to the plakin family of proteins, which are thought to be responsible for the 
dyskeratosis/necrotic keratinocytes [66, 67]. Interestingly, patients with erythema 
multiforme, a condition classically felt to be a non-immunologically mediated reaction 
pattern, can have a falsely positive indirect immunofluorescence on the classic PNP rat 
bladder substrate. There are recent reports of patients with erythema multiforme harboring 
anti-desmoplakin antibodies, though the pathogenicity of these autoantibodies has not yet 
been established [69, 70].   
 Finally, IgA pemphigus is distinguished by the presence of autoantibodies of the IgA 
subclass present on direct immunofluorescence in a classic intercellular space staining 
pattern.  Histologically, IgA pemphigus can be of the intraepidermal neutrophilic (IEN) 
variant or can be of the subcorneal pustular dermatosis (SPD) variant [71]. Dsc1 has been 
shown to be the target antigen in the IEN variant of IgA pemphigus, whereas the target 
antigen in the SPD variant of IgA pemphigus is likely a non-desmosomal antigen as shown 
by immuno-electron microscopy studies [72]. Pathogenicity studies are currently lacking. 
 To date, there are no descriptions of isolated anti-desmoplakin (outside of what is 
seen in PNP and erythema multiforme) or anti-plakoglobin mediated cutaneous disease. 
 
1.4. IMMUNOPATHOGENESIS OF AUTOANTIBODY-INDUCED BLISTERING IN 
PEMPHIGUS 
 PF and PV are the most studied variants of pemphigus. Researchers around the world 
are making their best efforts to explain how pemphigus autoantibodies cause disease.  An 
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association of susceptibility to pemphigus with certain HLA-DR and -DQ alleles has been 
suggested [73]. However, the exact mechanism and whether pemphigus autoantibodies 
induce loss of epidermal cell adhesion directly or indirectly is controversial.  Different 
mechanisms have been proposed such as: direct interference (steric hindrance), activation of 
transmembrane signaling that downregulates cell-cell adhesion, proteinase activation 
(plasminogen activator), and desmoglein internalization. There are two major theories that 
are the most accepted but still under debate: a) direct interference of desmogleins 
transinteraction by pemphigus autoantibodies, and b) activation of transmembrane signaling 
pathways and/or apoptosis by pemphigus autoantibodies that indirectly results in 
acantholysis. 
 
a) Direct interference of desmogleins transinteraction by pemphigus autoantibodies (steric 
hindrance theory):  Accumulated evidence from several epitope mapping studies indicates 
that pathogenic pemphigus autoantibodies target the amino-terminal end of Dsg1 and/or 
Dsg3 ectodomains [74-76]. Data based on the crystal structure of classical cadherins suggest 
that this N-terminal region harbors the adhesive interface of desmosomal cadherins [30, 77]. 
In addition, the pathogenicity of pemphigus IgG autoantibodies has been consistently 
demonstrated by passive transfer studies in neonatal mice [60, 78]. Moreover, not only the 
whole IgG molecule, but also the F(ab)2 and Fab fragments were found to be pathogenic, 
independently of complement or plasminogen activator [79-82], suggesting that due to their 
inability to cross-link cell-surface molecules, it is possible that they interfere directly with 
adhesion. Furthermore, monoclonal antibodies (AK23) derived from a PV mouse model that 
binds the functionally N-terminal adhesive interface of Dsg3 induced pemphigus vulgaris 
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lesions in mice, whereas monoclonal antibodies recognizing other regions of Dsg3 
ectodomain did not cause lesions in mice [83]. Using single-molecule atomic force 
microscopy (AFM), it has been shown that PV-IgG and AK23 monoclonal antibody directly 
inhibit Dsg3 homophilic binding under cell-free conditions, suggesting that direct inhibition 
of Dsg3 binding occurs in PV [84, 85]. Direct blocking of Dsg1 binding wasn’t observed by 
AFM, however, keratinocyte dissociation and loss of Dsg1- and Dsg3- coated microspheres 
to cultured keratinocytes were observed when using laser tweezer trapping [86], suggesting 
that acantholysis may not be solely dependent on direct interference of Dsg1-Dsg1 binding 
by pemphigus autoantibodies.  Recent studies using peptides against the desmoglein adhesive 
interface as well as tandem peptides (obtained by dimerization of two of the initial peptides) 
added evidence that direct inhibition contributes to acantholysis when the tandem peptide 
prevented acantholysis induced by PV-IgG, yet this was not the case when using PF-IgG. 
Thus, some investigators proposed that PV and PF acantholysis may involve different 
mechanism [87]. 
 
b) Activation of transmembrane signaling pathways and/or apoptosis by pemphigus 
autoantibodies. The direct interference of desmoglein transinteractions by pemphigus 
autoantibodies has been suggested to be insufficient to disrupt keratinocyte adhesion [33]. 
Therefore, additional cellular events may be needed to cause blistering.  Previous in vitro 
studies show that PV IgG induces cellular signaling events in cultured keratinocytes 
including a transient increase in intracellular calcium and inositol 1,4,5-triphosphate [88], 
activation of protein kinase C, and phosphorylation of Dsg3. These events may lead to 
internalization of Dsg3 from cell surface, therefore depleting Dsg3 from desmosomes [89-
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94]. Thus, activation of intracellular signaling within the target keratinocyte induced by 
binding of pemphigus IgG has been proposed to contribute to the loss of cell-cell adhesion. 
 Previous studies have shown that phosphorylation of p38MAPK and HSP25 (the 
murine homolog of human HSP27) occurs rapidly after exposure of cultured keratinocytes to 
pemphigus IgG and in the skin of mice injected with pathogenic IgG [95]. Also, 
phosphorylation of both p38MAPK and HSP27 has been observed in perilesional epidermis 
of pemphigus patients [96]. Furthermore, p38MAPK inhibitors block both histological and 
gross blister formation in the PF passive transfer model [95], suggesting that activation of 
p38MAPK is an early and key step in PF IgG-induced acantholysis. p38MAPK signaling has 
been implicated in other cellular responses such as desmosome assembly, cytoskeleton 
reorganization, changes of the cell cycle and apoptosis [97, 98]. Moreover, there is evidence 
that p38MAPK is involved in keratinocyte apoptosis [99, 100] and that DNA fragmentation 
and caspase activation are induced in the epidermis of PF IgG-treated mice [101]. 
Keratinocyte-derived and local production of apoptotic inducers such as nitric oxide 
synthase, Fas and Bcl-2, have also been detected in lesional skin of PF patients [102, 103] 
along with increased levels of Fas ligand in serum of pemphigus patients [104]. Futhermore, 
a biphasic activation of p38MAPK after the binding of pemphigus IgG has been recently 
demonstrated where the first activation peak is linked to acantholysis and the second peak 
coincided with apoptosis, suggesting that apoptosis occurs downstream to acantholysis in 
pemphigus [99]. However, other studies suggests that apoptosis occurs before acantholysis 
develops [101]. There is also the hypothesis that apoptotic signaling could precede 
acantholysis in the absence of apoptotic cell death [98]. More importantly, caspase inhibitors 
have been shown to block pemphigus serum-induced keratinocyte apoptosis. Thus, at 
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present, it is not clear which process precedes the other, but there is evidence that both are 
involved in pemphigus pathogenesis.  
 Another signaling pathway suggested to be involved is mediated through plakoglobin 
[105]. The observation was made that keratinocytes from plakoglobin-deficient mice were 
resistant to keratinocyte dissociation induced by PV IgG, suggesting that direct inhibition of 
Dsg binding may not be sufficient to cause acantholysis, and that plakoglobin could be part 
of a complex responsible for transferring the signal upon autoantibody binding from outside 
into the keratinocyte: “outside-in” signaling [106]. In addition, it has been shown that 
plakoglobin is involved in c-Myc repression, and c-Myc was also shown to be elevated in 
keratinocytes exposed to pemphigus autoantibodies [107, 108]. Nonetheless, the role of c-
Myc signaling in pemphigus acantholysis remains unclear. 
 
1.5. ENVIRONMENTAL FACTORS IN ENDEMIC PEMPHIGUS FOLIACEUS 
 The endemic form of pemphigus foliaceus, known as Fogo Selvagem (FS) which 
translates to “Wild Fire” in English because of the burning sensation that the disease causes, 
was first described in the early 1900s in certain areas of Brazil [109]. FS is highly endemic in 
the rural reservation of Limao Verde, in Mato Grosso do Sul, Brazil, where the prevalence is 
3.4% and an incidence of 1-4 new cases per year. Other less-characterized forms have been 
also reported in Colombia, Peru and Tunisia [62, 110, 111].  
 A unique characteristic of FS is it epidemiology. Autoantibody response against Dsg1 
in healthy individuals and disease prevalence are directly related to proximity to the 
reservation [112]. Several observations indicate that FS is triggered by exposure to an 
environmental agent(s) [113]. The geographical and temporal clustering of the cases as well 
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as the decreasing prevalence of FS upon improvement of living conditions, suggest the 
presence of an environmental antigen that may exhibit molecular mimicry with Dsg1. 
Circulating anti-Dsg1 autoantibodies in the serum of 42% of healthy individuals living in 
endemic Brazilian areas has been reported [65]. Moreover, anti-Dsg1 antibodies are also 
detected in FS patients before onset of disease as a mixture of IgG1 and IgG4 autoantibodies 
that recognize the EC5 portion of Dsg1 [75, 114].  An additional report showed that patients 
with disease transmitted by hematophagus vectors (black flies, sand flies and kissing bugs) 
possess antibodies against the extracellular EC5 domain of Dsg1 [115]. These findings 
suggest that saliva of these vectors may contain Dsg1 homologs that induce a non-pathogenic 
response to Dsg1. 
 Another feature of FS is the increased frequency of familial cases and the association 
to certain HLA-DR alleles [116]. These alleles are HLA-DRB1-0102, 0404, 1402 and 1406. 
The hypervariable region of the DRB1 gene of these alleles share the sequence LLEQRRA at 
positions 67-74, suggesting that this sequence may be critical for susceptibility to FS. It is 
possible that an environmental antigen induces an initial cross-reactive anti-Dsg1 non-
pathogenic response and only in individuals sharing these alleles is FS later developed. 
 IgG, IgM and IgE antibodies against Dsg1 are present not only in FS patients but also 
in healthy individuals living in Brazilian endemic areas [63, 117, 118]. Analysis of the 
hypervariable V genes of FS autoantibodies showed that they are antigen selected and this 
selection occurs before the onset of clinical FS [119].  
 Taken together, these observations suggest that recurrent and persistent exposure to 
an environmental cross-reactive antigen leads to the development of FS in genetically 
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predisposed individuals living in FS endemic areas. Furthermore, insect bites may deliver 
antigens/allergens that drive the production of cross-reactive anti-Dsg1 autoantibodies. 
 
1.6. ANIMAL MODELS IN FS 
 A passive transfer mouse model was developed to test in vivo pathogenicity of 
autoantibodies from FS patients [78].  Serum or IgG fraction from FS patient is given to 
neonatal mice by intradermal injection. The animals develop skin blisters and typical 
histological and ultrastructural features of the human disease, such as subcorneal vesicles [5]. 
The extent of disease correlates well with the indirect IF titers of human autoantibodies 
detected in the mouse skin. FS was also induced in these animals by injecting monovalent 
Fab fractions from FS autoantibodies [82], thus, the blistering in this animals is independent 
of complement activation. Despite the availability of recombinant human and mouse Dsg1, 
development of an active model for FS remains unsuccessful. 
 
1.7. CONCLUDING REMARKS 
 Although the mechanisms linking pemphigus IgG binding to acantholysis are not 
completely understood, much progress has been made in the characterization of target 
pathways that may help elucidate the primary event that drives pemphigus acantholysis. The 
interplay of direct interference and signaling mechanisms in pemphigus pathogenesis remains 
unclear, and this underscores the complexity and heterogeneity of pemphigus acantholysis. 
Studies towards the identification of the primary component(s) of the molecular mechanism 
of acantholysis will advance our understanding of pemphigus pathogenesis and therefore 
provide targets for the development of preventative and improved therapeutic strategies. 
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 FS provides a good model to study human autoimmune disease in which the auto-
antigen Dsg1 is fully characterized and the relevant autoantibodies are known to be 
pathogenic. In addition, the epidemiology of FS provides an opportunity to study the 
development of autoimmune disease in a well-defined, geographically limited population 
with a high prevalence of the disease. The saliva of hematophagus insects such as black flies 
have been suggested to harbor the cross-reactive antigen that induces a non-pathogenic anti-
Dsg1 response in healthy individuals living in FS endemic areas. However, the association of 
an environmental trigger with the pathogenic anti-Dsg1 response in FS remains unknown. 
 The objective of this dissertation is to identify the principal antigenic determinant in the 
extracellular domain of Dsg1 that is recognized by pathogenic FS autoantibodies and their 
association with a potential environmental agent.  Chapter 2, describes the identification of 
conformational epitopes for pathogenic IgG4 autoantibodies from FS patients living in LV, 
Brazil. Chapter 3 reports a non-infectious environmental agent that induces a potentially 
pathogenic anti-Dsg1 response in FS patients. Finally, Chapter 4 discusses the implications 
of the findings of this dissertation and future directions of this research.  
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CHAPTER II 
 
DISSECTING THE CONFORMATIONAL EPITOPES RECOGNIZED BY PATHOGENIC 
IgG4 ANTI-DESMOGLEIN 1 AUTOANTIBODIES IN ENDEMIC PEMPHIGUS 
FOLIACEUS 
 
2.1. INTRODUCTION 
Fogo Selvagem (FS), the endemic form of Pemphigus Foliaceus (PF), is a cutaneous 
autoimmune blistering disease that exhibits geographic clustering and a mortality of 100% 
without treatment. FS is highly endemic in the rural reservation of Limao Verde (LV), Brazil, 
where the prevalence is 3.5%, over 30 times higher than the non-endemic form seen in the 
US [1, 2].  
FS and PF are mediated by autoantibodies against the extracellular domain of the 
epidermal cell adhesion protein, Desmoglein 1 (Dsg1) [3]. The binding of these 
autoantibodies causes cell detachment, a process known as acantholysis, and leads to blister 
formation. The autoantibodies that mediate FS are predominantly of the IgG4 subclass [4, 5]. 
Serum or IgG autoantibodies from FS patients are pathogenic when passively transferred into 
neonatal Balb/c mice, eliciting blisters in the injection site and thus resembling the human 
disease [4]. Moreover, F(ab)2 and monovalent Fab fragments also reproduce human disease 
in the passive transfer model, indicating an Fc-independent mechanism in FS pathogenesis 
[6]. 
 Interestingly, 42% of healthy individuals living in LV, and thus at risk of developing 
FS, possess circulating IgG anti-Dsg1 autoantibodies [7] that are not pathogenic when tested
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in the passive transfer model [8] Thus, it appears that an environmental antigen(s) present in 
LV may trigger anti-Dsg1 autoantibody production, which in certain genetically predisposed 
individuals subsequently leads to pathogenic IgG4 secretion and clinical disease. Our recent 
report (see Chapter 3) strongly suggests that salivary antigens from sand flies and Dsg1 
contain cross-reactive epitopes that may be relevant in the progression of the pathogenic 
autoimmune response in FS [9]. 
Previous reports demonstrate that the progression from preclinical to clinical stage of 
disease is associated with a dramatic rise of IgG4 anti-Dsg1 autoantibodies [5]. In fact, 
detection of IgG4 anti-Dsg1 autoantibodies in serum of normal individuals living in LV are 
predictors of clinical disease in approximately 49% of the cases [10]. It has been suggested 
that the transition from preclinical to clinical disease in FS is associated with a switch from a 
mix of IgG1 and IgG4 anti-Dsg1 autoantibodies during pre-clinical stage to a predominantly 
IgG4-mediated anti-Dsg1 response at the onset of clinically active disease [5]. Thus, 
polarization of the humoral response to a predominantly IgG4 mediated response is a key 
step in the development of FS. 
The extracellular domain of Dsg1 is the target for PF and FS autoantibodies. Like 
other desmosomal cadherins, the extracellular domain of Dsg1 is composed of five calcium-
binding cadherin repeats (EC1 to EC5), with EC5 being proximal to the cell membrane (C-
terminal end). The epitopes recognized by FS autoantibodies are conformational and calcium 
dependent [11, 12]. The majority of pemphigus autoantibodies recognize the N-terminal 
region of Dsg1 [13, 14], and intramolecular epitope spreading in Dsg1 extracellular domain 
occurs in FS. We have previously demonstrated that anti-Dsg1 autoantibodies from healthy 
individuals and individuals in the preclinical stage recognize the EC5 domain, and upon 
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onset of clinical FS, a pathogenic response against the EC1 and/or EC2 domains of Dsg1 
arises [8].  
The majority of previous epitope mapping studies in pemphigus have been performed 
using domain swapped molecules and whole serum or IgG autoantibodies from PF or FS 
patients. These studies consistently suggested that clinically active PF/FS is driven by IgG 
autoantibodies specific for EC1 and/or EC2 domains of Dsg1 [8, 14]. However, the fine 
epitope specificity of IgG4 anti-Dsg1 autoantibodies has never been defined. In this study we 
have identified for the first time the conformational epitopes recognized by pathogenic IgG4 
autoantibodies from FS patients. Employing recombinant human Dsg1 (hDsg1) extracellular 
domain, highly purified FS IgG4 from 20 FS patients and the combination of Epitope 
Excision with Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-
MS/MS), we identified two dominant conformational epitopes on hDsg1. One located within 
the EC1 domain and another within the EC2.  Moreover, site-directed mutagenesis of the 
residues M133 and Q135 in hDsg1 (EC1), demonstrate that these residues are crucial in the 
binding of pathogenic IgG4 autoantibodies from FS patients.  
 
2.2. MATERIAL AND METHODS 
 
Sources of human FS sera:   
 Well-characterized sera from patients with FS (n=20) from Brazil, as well as sera 
from clinically healthy individuals from Limao Verde (n=1) and from the US (n= 1) were 
used for epitope mapping studies. The diagnosis of FS in these patients was established by 
clinical, histological, serological and epidemiological criteria [15, 16]. Serum samples from 
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other FS patients and sera from normal donors from the UNC Blood Bank were also 
available in our laboratory. Sera were collected following IRB policy from UNC-Chapel Hill 
(US) and University of Sao Paulo (Brazil).  
 
Purification of IgG4 autoantibodies from FS sera:  
 IgG4 autoantibodies were purified from sera by affinity chromatography using 
Capture Select® human IgG4 affinity matrix (BAC BV, Leiden, The Netherlands). The 
Capture Select human IgG4 affinity matrix contains a 12kD llama antibody fragment that 
specifically recognizes human IgG4 without cross-reacting with other human IgG subclasses 
1,2 or 3. Briefly, FS serum was loaded onto the matrix and later washed with PBS, pH=7.4. 
The matrix was eluted with 0.1M Glycine, pH=3.0. The bound fraction (elution) contained 
97% IgG4 and the unbound fraction contained 92% IgG1, with small amounts of IgG2 and 
IgG3. Both fractions were dialyzed against PBS pH=7.4, concentrated by ultrafiltration and 
stored at -20°C. In addition, total IgG was purified from a normal individual living in LV by 
Protein G-affinity chromatography using HiTrap Protein G HP cartridge (GE Healthcare). 
 Levels of total IgG and IgG subclasses in sera or purification fractions were measured 
by a sandwich quantitative ELISA established in our lab for this study, using goat F(ab)2 
anti-human IgG (Fab specific) as capture antibody, and monoclonal anti-human IgG or 
IgGsubclass horseradish-peroxidase conjugates as detecting antibodies. 
 
Plasmid constructs:  
 We have previously successfully constructed and expressed the entire extracellular 
domain of human Dsg1 in a baculovirus system [17, 18]. Briefly, cDNA encoding the entire 
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extracellular domain of Dsg1 including a COOH-terminal Histidine-tag was subcloned into 
the baculovirus transfer vector pVL1393 (BD Biosciences, San Jose,CA ) and later 
sequenced to verify sequence integrity.  
 We generated 4 domain-swapped molecules bearing the Dsg1 extracellular domain 
fragments EC1, EC1-2, EC4-5 and EC5 (Fig. 1). Recombinant Desmocollin 1 (Dsc1) was 
used as a backbone. Dsc1 is a desmosomal cadherin that shares extracellular structure with 
Dsg1; however, it is not recognized by typical pemphigus autoantibodies[19]. cDNA 
encoding the extracellular domain of Dsc1 was a kind gift from Dr Takahashi Hashimoto 
(Kurume University, Kurume, Japan) and also contains a C-terminal His-tag. cDNA 
fragments encoding various EC fragments of Dsg1 and Dsc1 ectodomain were amplified by 
PCR from full length human Dsg1 (GenBank accession: X56654) and human Dsc1 
(GenBank accession: X72925). The sequences of the PCR primers used are shown in Table 
I. The swapped-domain constructs were later ligated into the baculovirus transfer vector 
pEVmod and sequenced to verify the expected hybrid sequences. 
 In order to introduce point mutations in Dsg1 and Dsg4, we performed site directed 
mutagenesis using plasmid templates encoding the entire extracellular domains of hDsg1 and 
hDsg4 respectively. cDNA encoding the entire extracellular domain of human Dsg4 
harboring an E-tag and His-tag was cloned into pQE-Trisystem vector (QIAGEN, Inc.) as 
previously described [20]. The pQE-hDsg4-His plasmid DNA was kindly provided by Dr 
Masayuki Amagai (Keio University, Tokyo, Japan). Primers containing the desired mutations 
(Table I) were synthesized and used following manufacturer instructions for QuickChange 
Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). The mutated constructs 
were sequenced to verify the introduction of the desired mutations within EC1 and/or EC2 
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extracellular domains from hDsg1 and hDsg4, and to ensure the absence of additional 
mutations in the rest of the sequence.  
 
Table I. Primers used for construction of swapped-domain recombinant proteins and site    
   directed mutagenesis. 
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Expression and Purification of recombinant desmosomal proteins:  
 Plasmids encoding whole, chimeric and mutated proteins were cotransfected and 
expressed in a baculovirus expression system (BD BaculoGold, BD Biosciences) using Sf9 
insect cells in Sf-900™ III SFM containing 5% FBS (Invitrogen, Life Technologies Corp.) 
according to the manufacturer’s instructions.  High-Five insect cells cultured in Express-Five 
serum-free medium (Life Technologies Corp.) were used to produce recombinant soluble 
antigens by infection with the baculovirus stocks.  Next, recombinant proteins were purified 
from the culture supernatants by affinity chromatography using Ni-NTA cartridges 
(QIAGEN, Chatsworth, CA). Purified recombinant proteins were later dialyzed in Tris-
buffered saline buffer containing 5mM calcium (TBS-Ca2+) and stored at -80°C. 
 
Epitope Mapping by Epitope Excision and Mass Spectrometry:  
 Purified IgG4 was immobilized on CNBr-activated Sepharose 4B (GE Healthcare, 
Sweden) in compact reaction columns (CRC, USB Corporation, Cleveland, OH) and 
incubated with recombinant protein encompassing the entire extracellular domain of Dsg1. 
The Sepharose-IgG4-Dsg1 complex was then sequentially digested with sequencing grade 
chymotrypsin (Promega) for 1 hr at 37°C immediately followed by digestion with 
sequencing grade TPCK-treated trypsin (Worthington, Lakewood, NJ) for 20 minutes at 
37°C. Dsg1 peptides that remained bound to IgG4 after digestion were eluted with 0.1% 
Trifluoro acetic acid (ThermoScientific) and sequences were determined by mass 
spectrometry.  
 Samples were analyzed using a 4800 Plus Matrix-Assisted Laser Desorption 
Ionization Time of Flight Mass Spectrometry (MALDI TOF/TOF MS/MS) in conjunction 
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with Protein Pilot software (AB SCIEX, Foster City, CA). The samples were spotted on a 
stainless-steel target with !-cyano-4-32hydroxycinnamic acid matrix (Sigma). The 
instrument used has a YAG laser with "=355nm. The potential difference between the source 
acceleration voltage and the collision cell was set at 2kV. Calibration was done internally 
with self-digested TPCK treated trypsin (same as above). Peak absorbances in MS spectra are 
not indicative of the abundance of peptide species because of the differences in individual 
peptides ability to ionize. All analysis was done with Protein Pilot using an NCBI Mascot 
search.  
 The two most common peptides (epitopes) identified by this method were later 
synthesized at the Peptide Synthesis Core Facility at UNC. 
 
Molecular modeling of the extracellular domain of human Dsg1 and Dsg4:   
 The atomic structures of the extracellular domain of human Dsg1(hDsg1) and human 
Dsg4 (hDsg4) were predicted or modeled using 2 structural templates : 1) PDB ID 3Q2W 
(mouse N-cadherin); and 2) PDB ID 3Q2V (mouse E-cadherin).  
 Molecular modeling was performed at the Structural Bioinformatics Core Facility at 
UNC. The structural templates were identified using the HHpred Fold Recognition Server 
and the hDsg1 and hDsg4 homology models were built using the Modeller software package. 
The cadherin structural templates were in the homodimeric adhesive conformations. Thus, 
the structures of hDsg1 and hDsg4 were predicted in their homodimeric adhesive 
conformation.  
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Immunoprecipitation (IP):  
 All IPs were performed in TBS buffer containing 5mM CaCl2 (TBS-Ca2+).  200 µL 
of cell culture supernatant containing baculovirus-expressed Dsg1 or Dsg4, or 100 ng of 
purified WT or mutated hDsg1, were incubated with 2 uL of serum or purified IgG4 fractions 
in an end-over-end rocker at 4°C overnight. The following day, 25 µL of Protein G-Agarose 
slurry was added to the mix and incubated for 90 minutes at 4°C. After washing with TBS-
Ca2+ containing 0.1% Tween-20, each IP sample was subjected to SDS-PAGE and 
subsequent Western Blot. The probe used was anti-His-HRP conjugate (QIAGEN, Valencia, 
CA). 
 
Establishment of chimeric Dsg1 ELISA for detection of IgG4 autoantibodies:  
 Immunomicrotiter plates were coated with purified chimeric Dsg1-EC1 extracellular 
domain (200 ng/well) at 4°C overnight. After washing 5 times with TBS-Ca2+ buffer 
containing 0.05% Tween-20 (TBS-Ca2+/T-20), the plate was blocked with 1% BSA in TBS-
Ca2+/T-20 at room temperature for 1 hour.  Plates were then washed and incubated with 
duplicate samples of diluted serum (1:100) for 1 hour at room temperature. Following the 
washes, plates were incubated with a 1:500 dilution of horseradish-peroxidase (HRP)–
conjugated mouse anti-human IgG4 for 1 hour. The color development was achieved with the 
peroxidase substrate o-phenylenediamine. Results were expressed in index values calculated 
as previously reported [21]. A receiver-operating-characteristic (ROC) analysis was 
performed for the ELISA index values, generated from a set of 55 normal serum and 55 FS 
serum samples. An ROC curve was generated to display the sensitivity and specificity of the 
ELISA assay and to determine the cut-off. A sensitivity of 67% and a specificity of 98% 
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were provided by a cutoff of 7.54.  Index values above 7.54 were considered positive for this 
ELISA. 
 
Dsg1 and Dsg4 mutant ELISA for detection of IgG4 autoantibodies:  
 Purified WT or mutated Dsg1 and Dsg4 were used to coat immunomicrotiter plates 
(50 ng/well) at 4° C overnight. After 5 washes with TBS-Ca2+/T-20, the plate was blocked 
with 1% BSA in TBS-Ca2+/T-20 at room temperature for 1 hour.  Plates were then washed 
and incubated with duplicate samples of diluted serum or purified IgG4 fractions (1:300) for 
1 hour at room temperature. hIgG4 (Abcam®, Cambridge, MA) and normal human serum 
were used as negative controls. Following the washes, plates were incubated with a 1:1000 
dilution of horseradish-peroxidase (HRP)–conjugated mouse anti-human IgG4 for 1 hour. 
The color development was achieved with the peroxidase substrate o-phenylenediamine. 
 
Affinity Purification of IgG4 antigen- specific autoantibodies: 
 Affinity columns were prepared by immobilizing recombinant Dsg1 ectodomain in 
CNBr-activated Sepharose (GE Healthcare) following the manufacturer’s instructions. 
Purified IgG4 from FS serum was loaded into the Dsg1 affinity column. The successfully 
purified IgG4 anti-Dsg1 antibodies were then dialyzed against 1X PBS and stored at -20°C 
until further use.  
 
Passive Transfer studies: 
 Balb/c neonatal mice (24-36 hrs old, body weight 1.4-1.8 g) were intradermally 
injected as previously described [22] with different quantities (contained in a volume of 100 
 40 
µL) of either IgG4 or IgG1 purified fractions from FS sera. Commercially available hIgG4 
(Sigma Aldrich) was injected as a control.  After 18-24 hrs post-injection, the skin of the 
mice was evaluated for blisters. Skin biopsies were obtained for histology and direct 
immunofluorescence analysis. 
 
2.3. RESULTS 
2.3.1.   IgG4 anti-Dsg1 autoantibodies from FS sera are pathogenic 
To investigate the Dsg1 epitopes recognized by FS IgG4 autoantibodies, we first purified 
IgG4 from the serum of one FS patient and tested its pathogenicity using the passive transfer 
model. We found that the llama anti-human IgG4-Sepharose matrix was a very effective 
affinity chromatography method to purify IgG4 from FS sera. The bound fraction contained 
97% IgG4, and the unbound fraction contained 92% IgG1 as measured by quantitative IgG4 
and IgG1 ELISAs. Both fractions showed the classic staining pattern on the epidermal 
intercellular spaces by indirect IF. Importantly, when these fractions were passively 
transferred to neonatal Balb/c mice, only the IgG4 fraction was pathogenic, inducing 
extensive blistering in these animals (Fig. 2).  In contrast, the unbound IgG1 fraction was not 
pathogenic, even at doses 4 times higher than IgG4 dose. These findings were confirmed 
using a second FS serum. 
 To further analyze the domains of Dsg1 that are bound by these two fractions (IgG4 
and IgG1), we employed 4 domain-swapped molecules bearing the EC1, EC1-2, EC4-5 and 
EC5 domains of Dsg1 grafted on the extracellular domain of Dsc1. The C-terminal end of 
these chimeric molecules has a His-tag (Fig. 1). We observed that IgG4 and IgG1 fractions 
from the same patient immunoprecipitated EC1 and EC5 domain-swapped molecules (Fig. 
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2). Thus, these findings suggest that while IgG4 and IgG1 bind Dsg1 at epitopes within EC1 
and EC5 domains, only the IgG4 autoantibodies are pathogenic and therefore responsible for 
blister formation.  
 The prevalence of IgG4 anti-EC1 autoantibodies in FS sera was tested by 
ELISA (Fig. 3). We tested the sera of 55 FS patients and 55 normal donors, which included 
23 sera from endemic areas of FS in Brazil and 22 from UNC Blood Bank. IgG4 anti-EC1 
autoantibodies were detected in 37 FS sera (67%) and only in one of the normal human sera 
from endemic areas (Fig. 3). These findings strongly support the hypothesis that the presence 
of anti-EC1 IgG4 autoantibodies is a key hallmark of FS. 
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Figure 1.   Domain-swapped hDsg1/Dsc1 recombinant proteins produced in baculovirus 
expression system. A) Molecular structures of 4 domain-swapped molecules bearing different 
regions of hDsg1 ectodomain using Dsc1 as a backbone. B) Immunoblot of the insect cells 
supernatants containing the secreted recombinant proteins. Monoclonal anti-His antibody was 
used as a probe. The double band is due to the expression of mature and immature forms of 
recombinant proteins in baculovirus system. S=signal sequence, P=propeptide sequence. 
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Figure 2.     Analysis of IgG4 and non-IgG4 autoantibodies from FS patient serum by IP and Passive 
Transfer. Top panel: IP/IB using purified swapped-domain proteins. Monoclonal anti-His antibody was 
used as a probe. IgG4 (97% pure fraction) and non-IgG4 (92% IgG1) recognized the EC1 and EC5 
domains of Dsg1. Bottom panel: Different doses of both fractions were passively transferred to neonatal 
Balb/c mice. Bottom left: mouse injected with 100 ug of IgG4 showed extensive blistering at the injection 
site.  Bottom right: Mouse injected with 400 ug of non-IgG4 did not develop blisters. Two mice per group 
were used. 
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2.3.2.    Dominant conformational epitopes for pathogenic IgG4 FS autoantibodies are 
  located within EC1 and EC2 regions of Dsg1 extracellular domain. 
To further refine the mapping of the epitopes recognized by IgG4 anti-Dsg1 autoantibodies, 
we purified IgG4 fractions from 20 FS sera using the llama anti-human IgG4-Sepharose 
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Figure 3.    Prevalence of IgG4 autoantibodies against Dsg1(EC1) by ELISA. Purified swapped-
domain protein bearing EC1 domain of Dsg1 was used to coat ELISA plates in order to test the 
immunoreactivity of IgG4 anti-EC1 across human sera: FS (n=55), Brazil-NHS (n=23), UNC-
NHS (n=22). Monoclonal anti-human IgG4-HRP antibody was used as a secondary antibody. A 
cutoff of 7.54 defined positive sera. NHS= normal human sera. 
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matrix. The IgG4 fraction from each serum was immobilized on CNBr-activated Sepharose 
followed by incubation with purified recombinant human Dsg1 extracellular domain. As 
described in Methods and shown in Fig. 4, the immobilized immune complex, i.e. hDsg1-
IgG4, was digested with trypsin/chymotrypsin and the IgG4-protected Dsg1 peptides 
(epitopes) were later eluted and analyzed by MALDI-TOF/TOF-MS/MS. 
 
 
 
 
 
 
 
!"#$%&'()*+&,,-,*)%%
./0*12%
300/41,15&.%
3#67%89:;<%
!"#$%&'(")
!"#$%&'(") !"#$%&'(")
*+,-").',/0)
#"#10"()
!"#$%&'(")
2%($)
3!43!)
567"(1'/)'8)
,/.',/0)5(79)
Figure 4.  Epitope mapping by epitope excision and mass spectrometry.  A schematic 
representation of the epitope mapping strategy used in this study. Immobilized pure 
IgG4 binds to recombinant Dsg1 extracellular domain, followed by digestion of the 
unbound portions with chymotrypsin/trypsin. After several washes, bound peptides are 
dissociated and analyzed by MALDI-TOF/TOF-MS/MS. 
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Two dominant epitopes were identified. One is located within EC1 (residues A129 – 
R144) and the second is within EC2 (residues Q201-R213). The epitope in EC1 was 
recognized by 19/20 FS sera (95%) and the epitope in EC2 was recognized by 17/20 FS sera 
(85%). Additional epitopes located within the propeptide sequence, EC4, and EC5 were also 
identified but in lower frequencies (5-45%). The summary of these results are shown in 
Tables II and III. 
To validate our epitope mapping results we utilized the IgG4 fraction purified from 
healthy human serum, which did not recognize any epitopes in Dsg1 by our epitope excision 
method. Additionally, when recombinant hDsg1 extracellular domain was digested with 
trypsin/chymotrypsin prior to incubation with FS IgG4-Sepharose, no relevant epitopes were 
detected by MALDI-MS/MS. These results suggest that the majority of identified epitopes 
bound by FS IgG4 are conformational. The two major epitopes (peptides) identified within 
EC1 and EC2 were synthesized alone or linked to biotin. The synthetics peptides were used 
to perform ELISAs and inhibition assays. None of the FS sera or purified IgG4 fractions 
recognized the synthetic peptides, as demonstrated by direct ELISA, or ELISAs on 
Streptavidin-coated microtiter plates (data not shown). These results strongly suggest that 
both epitopes are conformational.  
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Table III. Frequency of IgG4 anti-Dsg1 autoantibodies targeting conformational epitopes 
        identified by MALDI-MS/MS analysis. 
 
Region in Dsg1 
ectodomain Epitope Amino Acid sequence 
 
Frecuency of FS IgG4 
(n=20) 
 
Propeptide WHSIR 45 % 
EC1 
FAAACR 5 % 
EGEDNSKR 5 % 
IHSDCAANQQVTYR 5 % 
ALNSMGQDLERPLELR 95% 
EC2 
QEPSDSPMFIINR 85 % 
NTGEIR 10 % 
TMNNFLDR 35 % 
EC4 
VGDFVATDLDTGRPSTTVR 5 % 
YVMGNNPADLLAVDSR 15 % 
YQGTILSIDDNLQR 40 % 
EC5 DLLSDNVHF 25 % 
 
 
Molecular modeling of the Dsg1 extracellular domain was performed to predict the 
atomic structure of the molecule and the location of the EC1 and EC2 epitopes recognized by 
FS IgG4.  As shown in Fig. 5, the structure of hDsg1 was predicted in its homodimeric 
adhesive conformation. One monomer is dark gray and the second monomer is in light grey. 
The dimeric adhesive conformation can be recognized by the extension of the light and dark 
strands in EC1 and their interactions with the other monomer. A pocket within EC1 of the 
first monomer will contain its own W51 in the monomeric state but contains the W51 from 
the second monomer in the swapped state, which is the adhesive conformation. The first 2 
residues (AL) of the epitope in EC1: A129-R144, are part of the cell-adhesion recognition 
site RAL of Dsg1, a motif important for maintaining desmosomal adhesion.  
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Figure 5.   Location of 2 conformational epitopes recognized by FS IgG4 autoantibodies in a 
predicted model of hDsg1 extracellular domain.  Predicted atomic structure of hDsg1 was 
generated by molecular modeling using classical cadherins as a template. Homodimeric adhesive 
conformation model is shown with one monomer in light gray and the second monomer in dark 
gray. A) Anterior view of hDsg1 homodimer showing epitope in EC1: ALNSMGQDLERPLELR 
in red. B) Posterior view of hDsg1 homodimer showing the epitope in EC2: QEPSDSPMFIINR in 
green. C) Blow up of hDsg1 homodimer in the context of EC1 and EC2 domains. Note that the 
extension of the light and dark strands in EC1 defines the dimeric adhesive conformation. A 
pocket within EC1 of the first monomer will contain its own W51 in the monomeric state but 
contains the W51 from the second monomer in the swapped state, which is the adhesive 
conformation. D) Bottom view of hDsg1 dimer showing the nearness of the EC1 epitopes in the 
dimer conformation. R of RAL adhesive motif is in dark blue and AL residues are shared with the 
EC1 epitope (red). Calcium binding sites are in light blue. Two N-glycosilation sites in orange. 
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2.3.3   Residues M133 and Q135 in EC1 region of hDsg1 extracellular domain are key 
components of the conformational epitope for pathogenic IgG4 autoantibodies in FS. 
 In order to define the key components of the conformational epitope for pathogenic 
IgG4 autoantibodies in FS, we first compared the amino acid sequence of the two major 
epitopes identified in this study across homologous cadherins. The alignment of both 
epitopes sequences in hDsg1 showed that there are more conserved amino acids in hDsg4 
than in other desmosomal cadherins. This observation is in agreement with previous reports 
that anti-Dsg4 antibodies from pemphigus patients cross-react with Dsg1 but are not 
pathogenic in the mouse model [20]. Moreover, Dsg4 extracellular domain is not recognized 
by the 20 FS sera used in this study by ELISA. 
The sequence of the conformational epitope in EC1 of hDsg1 differs in two residues 
from hDsg4 (residues M133 and Q135), whereas in the EC2 epitope of Dsg1, three residues 
are different from Dsg4 (residues D205, S206 and I211) (Fig. 6B). Two point-mutated 
recombinant Dsg4 extracellular domains were generated by site-directed mutagenesis: Dsg4-
MEC1 (containing M133 and Q135 from Dsg1) and Dsg4-MEC2 (containing D205, S206 
and I211 of Dsg1). In addition, we generated two point-mutated recombinant Dsg1 
extracellular domains:  Dsg1-MEC1 (containing R133 and E135 from Dsg4) and Dsg1-
MEC2 (containing G205, A206 and L211 from Dsg4) (Fig. 6C). 
The four mutated recombinant proteins were tested by ELISA in order to determine 
the effect of the mutations in the reactivity of IgG4 autoantibodies from 20 FS against Dsg1 
or Dsg4. Mutation of residues M133 and Q135 in Dsg1 (Dsg1-MEC1) dramatically reduced 
(77%) the reactivity of IgG4 autoantibodies against Dsg1, demonstrating the crucial role that 
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these residues play in forming the recognized epitope (Fig. 7A). Mutations in EC2 (Dsg1-
MEC2) did not show significant difference (13% reduction) in reactivity of IgG4 against 
Dsg1. On the other hand, mutations in Dsg4 did not restore recognition of this molecule by 
IgG4 autoantibodies from FS patients (Fig. 8), suggesting that there may be additional 
residue(s) in other regions of Dsg1 that are absent in Dsg4 and are necessary to achieve the 
proper protein conformation that makes the conformational epitope accessible to IgG4 
autoantibodies. 
To further confirm these results, we performed immunoprecipitation (IP) using 
recombinant hDsg1 extracellular domain and the two point-mutated recombinant hDsg1 
proteins. By IP, IgG4 from FS patients did not immunoprecipitate Dsg1-MEC1 but did 
recognized Dsg1-MEC2 (Fig. 7B), mirroring our ELISA results. Taken together, our results 
indicate that residues M133 and Q135 located in EC1 region of Dsg1 extracellular domain 
are required to achieve the proper conformation of the epitope for pathogenic IgG4 
autoantibodies in FS. 
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Figure 6.    Site directed mutagenesis in the extracellular domains of hDsg1 and hDsg4.  
 A) Amino acid sequence of the N-terminal end of Dsg1. Showing the sequence of EC1 
domain (purple box), EC2 domain (blue box), signal sequence (black box) and propeptide 
sequence (orange box). Peptides recognized by FS IgG4 antibodies in EC1 and EC2 are in 
red and green respectively. RAL sequence is highlighted. B) Alignment of amino acid 
sequences of the two dominant conformational epitopes identified in hDsg1 with its 
homolog cadherin hDsg4 that is not recognized by FS IgG4 autoantibodies. Non-
conserved residues are labeled with a star (*). C) Diagram of constructs of wild type (WT) 
and point-mutated (MEC1 or 2) molecules expressed in baculovirus system. Residues 
133,135,205,206 and 211 were replaced in the extracellular domain of hDsg1 or hDsg4 by 
site-directed mutagenesis. 
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Figure 7. Mutation of residues M133 and Q135 in EC1 domain of Dsg1 dramatically 
reduces the binding of IgG4 autoantibodies to Dsg1 extracellular domain. A) Purified 
IgG4 fractions from 20 FS sera were tested by ELISA for reactivity against Dsg1-WT and 
Dsg1-mutants. Dsg1-MEC1 (with mutations in M133 and Q135) showed diminished 
recognition (77%) by IgG4 FS autoantibodies. Mutations in EC2 showed no significative 
reduction (13%) in binding by IgG4. Commercially available human IgG4 (Abcam) and 
normal human serum (NHS) or IgG purified from NHS were used as negative controls in 
each ELISA. Monoclonal anti-hIgG4-HRP conjugated antibody was used as a secondary 
antibody. Mean O.D. values are shown. B) Immunoprecipitation (IP) results from IgG4 
fractions purified from 3 FS patients are shown. Fractions were pathogenic in mouse passive 
transfer model. hDsg1 with mutations in EC1 (M133 and Q135) is not recognized by any of 
the 3 fractions. Monoclonal anti-His-HRP conjugated antibody was used for detection. 
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Figure 8.  Detection of IgG4 autoantibodies against Dsg4-WT and Dsg4-mutants by 
ELISA. Purified IgG4 fractions from 20 FS sera were tested for reactivity against Dsg4 
WT and Dsg4 mutants. Commercially available human IgG4 (Abcam) and normal 
human serum (NHS) or IgG purified from NHS were used as negative controls in each 
ELISA. Monoclonal anti-hIgG4-HRP conjugated antibody was used as a secondary 
antibody. Mean O.D. values are shown. 
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2.4. DISCUSSION 
 In this study, we have successfully located two dominant conformational epitopes 
within the EC1 and EC2 domains of Dsg1 by using improved IgG4 purification techniques 
and a powerful epitope mapping strategy. Most importantly, we identified 2 residues within 
the calcium- and conformational-dependent EC1 epitope that appear to be required for the 
binding of pathogenic IgG4 anti-Dsg1 autoantibodies.  
 The low levels of IgG4 subclass present in normal human serum (4% of IgG) [23] has 
made  purification of IgG4 antibodies challenging. Our group and others have used different 
separation methods such as Ion Exchange Chromatography on DEAE or a combination of 
positive and negative affinity chromatography using monoclonal antibodies [4, 24, 25]. 
However, these “multistep” methods have limitations such as time, cost, efficiency, and most 
importantly, the so-called IgG4 enriched fractions exhibit significant IgG1 contamination 
(12-30%). In this study we overcame such limitations to obtain highly purified IgG4 fractions 
by using an affinity matrix containing a 12kD llama antibody fragment that recognizes 
human IgG4 without cross reactivity to other human IgG subclasses 1,2 or 3.  The use of 
llama antibodies as affinity ligands offers several advantages over conventional antibodies 
[26-28]. These antibodies lack the entire light chain and the CH1 domain found in 
conventional antibodies. Thus the antigen binding domain is a 12-15kD single protein, called 
VHH, which is much more stable compared to standard monoclonal antibodies [28-30]. 
Using this one step affinity purification method, we obtained 97% pure IgG4 fractions from 
FS patients’ sera. Purified IgG4 was immunoreactive when tested by IP or ELISA and in the 
passive transfer mouse model. Furthermore, the observation that both bound (97% IgG4) and 
unbound fractions (92% IgG1) targeted the same domains in Dsg1 extracellular domain (EC1 
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and EC5) (Fig. 2) indicated the importance of using a highly purified reagent (IgG4) in order 
to dissect the specific epitope(s) within those domains.  
 Epitope spreading is a pathogenic process that leads to relapse and chronic 
progression of an autoimmune disease [31-33]. We have previously suggested that 
intramolecular epitope spreading occurs in FS [8], where the anti-Dsg1 autoimmune response 
evolves from a non-pathogenic response to the EC5 portion of the Dsg1 extracellular domain 
in healthy individuals to a pathogenic response against the EC1 and EC2 in FS patients.  
 The identification of the specific epitope(s) recognized by pathogenic FS antibodies is 
a key step in understanding the pathogenesis of FS blister formation. Previous attempts to 
elucidate the specificity of pemphigus autoantibodies within Dsg1 have shown that blister 
formation is driven by IgG autoantibodies specific for the N-terminal end of Dsg1 
extracellular domain [14, 34, 35], which contains the adhesive interface of the molecule 
responsible for maintaining desmosomal adhesion[36]  However, the fine epitope specificity 
of IgG4 anti-Dsg1 autoantibodies remains elusive. In this study, we refine previous epitope 
mapping findings and identify critical components of the conformational epitope for IgG4 
autoantibodies from FS.   
 We prepared a recombinant Dsg1-Sepharose matrix to purify IgG4 anti-Dsg1 
antibodies from the IgG4 fractions obtained from FS serum. We successfully obtained IgG4 
anti-Dsg1 antibodies and they were also pathogenic when passively transferred into neonatal 
mice. Only 10 µg of anti-Dsg1 IgG4 per mouse were needed to produce extensive blister in 
the mouse, equivalent to the blistering induced by injection of 100 µg of IgG4 fraction (Fig. 
2). This result, coupled with the observation that injection of a higher dose (4-fold) of the 
unbound fraction from the previous step (containing 92% IgG1) doesn’t induce blistering in 
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the mouse model, strongly suggests that the epitope(s) recognized by IgG4 autoantibodies is 
responsible for the blister formation in FS. 
 Consistently with previous findings [8] the majority of IgG autoantibodies from FS 
patients sera targeted the EC1 region of the Dsg1 extracellular domain, when using domain-
swapped recombinant proteins in IP assays (data not shown).  In addition, 67.3% (33/55) of 
FS patients serum possessed circulating IgG4 specific for the EC1 region of Dsg1 when 
tested by ELISA using domain-swapped Dsg1 chimeric protein. This result suggests that the 
epitope for pathogenic IgG4 autoantibodies may be located within EC1 region of Dsg1 
extracellular domain.  
 Previous studies have shown that the binding of pemphigus antibodies is calcium-  
and conformation-dependent [11, 12], which indicates that most of these autoantibodies 
recognize three-dimensional structures that depend on protein folding. Unfortunately and to 
the best of our knowledge, there is no 3D crystal structure of Dsg1 available, making it 
difficult to pinpoint the specific sequence that constitutes the epitope for pemphigus 
autoantibodies.  
 In this study, we introduce the use of proteomics to the pemphigus field. Epitope 
mapping for pathogenic IgG4 autoantibodies from FS patients is assessed for the first time by 
epitope excision and mass spectrometry. Epitope excision is a form of protective assay, 
where the Dsg1-bound IgG4 protects the epitopes sequences from digestion because of the 
known resistance of the immobilized antibody to proteolysis [37] and the use of non-
denaturing conditions, which allows the antigen to retain its conformation. Using polyclonal 
IgG4 fractions, we were able to identify two dominant conformational epitopes that are 
consistently recognized by almost all of the 20 FS patients (95% and 85%). We identified 
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additional epitopes but in much lower frequencies (5-45%). These additional epitopes may 
not be relevant to disease and/or may have been part of the epitope spreading cascade in 
earlier, perhaps non-pathogenic, stages of FS.  
 Using molecular modeling we predicted the atomic homodimeric structure of the 
Dsg1 extracellular domain using classical cadherins as a template. We localized the 
sequences of the two dominant conformational epitopes in EC1 and EC2 respectively. Both 
epitopes were flanked by calcium-binding sites in the model and were in opposite faces of 
the molecule. The most common epitope with residues 129A-144R located within EC1 
shares 2 residues (129A and 130L) with the RAL sequence of Dsg1, that is part of the 
adhesive interface of this molecule. In addition, the nearness of the two EC1 epitopes from 
the dimer conformation suggests that the binding of IgG4 to this epitope may interfere with 
the dimer formation, depending on which residues it binds. The epitope with residues Q201–
R213 located within EC2 seems to be far from the adhesive interface; however, a calcium-
binding site separates this epitope from the one in EC1. It is possible that upon binding of 
calcium ions to Dsg1, the protein folds into a conformation that brings both epitopes into 
proximity, allowing the displayed epitope to incorporate residues from EC1 and EC2. 
Availability of Dsg1 crystal structure will be useful to prove this hypothesis. 
 Although we identified two conformational epitopes that are recognized by IgG4 
autoantibodies from FS patients, further testing is needed to determine whether one or both 
of the epitopes are relevant to disease. Alignment of both epitopes sequences of Dsg1 with 
Dsg4 extracellular domain reveals that residues M133, Q135, D205, S206 and I211 are not 
conserved in Dsg4. Replacement of these residues in Dsg1 and Dsg4 by site-directed 
mutagenesis demonstrated that residues M133 and Q135 in EC1 of Dsg1 extracellular 
 58 
domain are required for the binding of IgG4 autoantibodies from FS patients, suggesting that 
these residues may define the conformational epitope for pathogenic IgG4 autoantibodies in 
FS. Interestingly, the replacement of residues in EC1 or EC2 of hDsg4 in order to mimic both 
epitopes from hDsg1 did not cause any effect in the binding by IgG4 when tested by ELISA 
or IP. Therefore, there may be additional residues in other regions of Dsg1 that are absent in 
Dsg4, which help to create the conformation that displays the epitope in EC1. This may be 
the case for the epitope in EC2, where mutation of the three residues was not sufficient to 
block the binding of IgG4 to Dsg1. It is also possible that the IgG4 autoantibodies specific 
for the epitope in EC2 constitutes a small population of autoantibodies that may or may not 
be pathogenic.  
 This study identifies two dominant conformational epitopes recognized by pathogenic 
IgG4 autoantibodies in FS. In addition, it narrows down the residue requirement in EC1 for 
the binding of these autoantibodies. These findings provide a basis for targeted epitope-
specific preventative and improved therapeutic strategies, as well as for identification of 
molecular mechanisms and/or environmental triggers(s) for FS. 
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CHAPTER III 
INDUCTION OF IgG4 ANTI-DESMOGLEIN 1 ANTIBODIES BY HEMATOPHAGUS 
INSECTS BITES1 
 
3.1. INTRODUCTION 
 It is an accepted assumption that the interaction of unknown environmental factors 
with susceptibility genes of the host ensues the immune system to react to self-antigens 
causing an spectrum of autoimmune diseases [1].  The common thread amongst autoimmune 
diseases is the obscure etiology.  Human organ specific autoimmune diseases targeting the 
skin comprise the pemphigus group, where pathogenic IgG4-restricted, anti-epidermal 
autoantibodies cause epidermal cell detachment that leads to blister formation [2].  The 
antigen recognized by these autoantibodies in PF is Dsg1.  The idiopathic, non-endemic form 
of PF is known worldwide, whereas an endemic variety, FS is seen in certain regions of 
subtropical Brazil [3]. FS shows similar clinical, histological and immunological features to 
non-endemic PF, except for the unique epidemiology of FS.   A case-control epidemiological 
study of FS in Brazil suggested that certain living conditions and exposure to hematophagous 
insect bites were risk factors of FS [4].  Exposure to bites of three insects is suspected to be 
linked to FS: Lutzomyia longipalpis (sand flies), reduviids (kissing bugs) and simuliids 
                                                
1 Partially reproduced from: Qian,Y., Jeong, J.S., Maldonado, M., Valenzuela, J.G., Gomes, R., Evangelista, F., 
Qaqish, B., Aoki, V., Hans, G.Jr., Rivitti, E.A., Eaton, D., Diaz, L.A. Cutting Edge: Brazilian pemphigus foliaceus 
anti-Desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen.  J Immunol. 2012. 189(4): 1535-
1539. 
F. Evangelista contributed with the generation and purification of rDsg1, immunoprecipitation assays and additional 
experiments that are not part of the text, but supportive of the overall conclusion.  
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(black flies).  They are vectors of leishmaniasis, Chagas disease and onchocerciasis 
respectively.  Moreover, the sera of a large number of these patients possess anti-Dsg1 
autoantibodies [5].   
A recent study has demonstrated that not only IgM and IgG4 anti-Dsg1 
autoantibodies are detected in the sera of FS but also IgE [6].  It is remarkable that IgG4 anti-
Dsg1 autoantibodies are restricted and pathogenic in FS; however, the mechanisms involved 
in the emergence of these autoantibodies are completely unknown.  The endemic nature of 
FS and the circumstantial evidence presented above allow us to test the hypothesis that 
salivary gland antigens from hematophagus insects are the source of sensitizing antigen that 
triggers the autoimmune disease in FS.  We selected a well-defined system provided by 
Lutzomyia longipalpis, where the salivary gland proteins are well characterized [7, 8].  In this 
investigation we show that IgG4 autoantibodies from FS sera recognized salivary gland 
antigens from Lutzomyia longipalpis (SGLL).  The major SGLL antigenic component 
recognized by FS sera is LJM11. In addition, sera from mice immunized with LJM11 also 
recognize human recombinant Dsg1.  These results strongly support the notion that LJM11 
induces cross-reactive antibodies in FS patients and experimental animals.  This is the first 
evidence that a non-infectious agent may trigger a human autoimmune disease via molecular 
mimicry. 
 
3.2. MATERIAL AND METHODS 
Serum samples and anti-Dsg1 monoclonal antibodies from FS patients 
FS sera (N = 45) and two IgG4 anti-Dsg1 monoclonal antibodies (4E4 and 2D11) derived 
from FS patients [9], were used.  Sera from healthy donors (n = 43) from the University of 
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North Carolina blood bank were included as controls (HC-UNC). Ten sera from normal 
donors living in Brazilian endemic areas of FS were also included in some of the studies 
(HC-endemic).  This study was approved by the Institutional review boards from universities 
of North Carolina, Chapel Hill and Sao Paulo, Brazil.  The H and L chains of 4E4 and 2D11 
[9] were cloned into pComb3XSS vector and expressed in Top10 F’ cells [10]. A GST-tag 
was introduced to the 4E4 construct to increase the solubility of the recombinant 4E4 scFv, 
and 4E4-GST scFv was produced and purified by Genscript (Piscataway, NJ). The 4E4-GST 
scFv was not pathogenic when tested by passive transfer into neonatal mice [2] and the 
dispase assay [11] using concentrations up to 30ug/dose and 5ug/ml of the antibody 
respectively. 
 
Recombinant Human Dsg1, Sand fly salivary gland extract, and sand fly salivary proteins  
Recombinant Dsg1 was generated and purified as described [12]. Salivary gland extracts 
from Lutzomyia longipalpis (SGLL) and SGLL proteins LJM11, LJM17, and LJL143 were 
generated at the Laboratory of Malaria and Vector Research, NIAID by Valenzuela [8, 13].   
 
ELISA 
IgG4 anti-Dsg1 and anti-SGLL ELISAs were conducted as described in previous 
communications [6, 9, 14].  The ELISA assay to detect IgG4 antibody activity against 
LJM11, LJM17 and LJL143 SGLL proteins was also conducted as above with some 
modifications. Stripwell Microplates (Corning, Lowell, MA) were coated with 50ng/well 
with either LJM11, or LJM17, or LJL143 proteins.  A 1:100 dilution of each of FS sera or 
scFv 4E4 and 2D11 anti-Dsg1 monoclonal antibodies (50ng/ml) was added and incubated.  
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The bound IgG4 antibodies from serum samples or scFv antibodies were detected with anti-
human IgG4 HRP (Zymed, San Francisco, CA) or anti-HA HRP conjugate (Roche, 
Indianapolis, IN), respectively.  Anti-Dsg1 ELISA using SGLL recombinant proteins 
immunized mouse sera was conducted according to regular anti-Dsg1 ELISA described 
above with following modification.  The mouse serum was diluted 1:500 and goat anti-mouse 
IgG (Fc fraction) HRP conjugate (Jackson ImmunoResearch, Carlsbad, CA) was used to 
detect anti-Dsg1 antibodies from mouse sera. 
 
Immunoprecipitation (IP) 
Pan mouse IgG magnetic Dynabead (Invitrogen, Carlsbad, CA) was used for the IP 
according to manufacturer’s instructions with modifications.  Mouse anti-human IgG4 and 
Mouse anti-GST tag monoclonal antibodies (Zymed, San Francisco, CA) were used for the 
IP of sand fly salivary gland proteins LJM11, LJM17, and LJL143.  All IPs were proceeded 
in the TBS buffer containing 0.5% Tween-20 and 5mM CaCl2 (TBS-T-Ca), plus 0.1% BSA. 
First the Dynabeads (20µl of slurry) were blocked with 0.1% BSA in TBS-T-Ca for 1 hour at 
room temperature (RT) and incubated with mouse anti-GST (for 4E4-GST) or mouse anti-
human IgG4 (for serum samples) for 1 hour at RT, and then 4E4-GST or human serum 
samples for 2 hours at RT.  Finally Dynabeads were incubated with LJM11, LJM17, and 
LJL143, respectively for 2 hours at RT.  For IP using SGLL recombinant protein immunized 
mouse sera, 2µl of each mouse serum samples were incubated with 450µl recombinant Dsg1 
cell culture supernatant for 2 hours at RT and then with 20µl of Dynabead slurry for 1 hour. 
Each IP sample was subjected to SDS-PAGE and subsequent Western Blot.  The membranes 
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were probed with anti-His HRP (Qiagen, Valencia, CA) and the bands revealed with 
chemiluminescent substrate (Pierce, Rockford, IL). 
 
Statistical Analysis 
Groups were compared by t-test.  Correlation analysis was by the Pearson correlation. 
 
3.3. RESULTS 
 
3.3.1.  FS patients possess IgG4 antibodies against Lutzomyia longipalpis salivary gland 
antigens.  
 We have recently reported that FS patients possess significantly higher levels of IgG4 
anti-Dsg1 antibodies than control groups from non-endemic areas of Brazil and US [6].  It is 
possible that generation of these anti-Dsg1 autoantibodies maybe secondary to exposure and 
sensitization to an environmental antigen(s).  The sera from FS patients, and healthy controls 
from US (HC-UNC) were tested for IgG4 antibody activity against SGLL by ELISA.  As 
shown in Fig. 1A, the index values of IgG4 anti-SGLL antibodies are significantly higher in 
FS patients (n=45) than HC-UNC controls (n=43) (p<0.001).  The IgG4 anti-SGLL antibody 
response in the FS group was significantly correlated with both the IgG4 anti-Dsg1 (Pearson 
correlation: r=0.56, p<0.0001) (Fig. 1B).  These findings strongly suggest that the generation 
of potentially pathogenic IgG4 anti-Dsg1 in FS may be associated with the antigenic 
stimulation produced by salivary antigens from hematophagous insects.   
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Fig 1. A. Boxplot analysis of the IgG4 and IgE response in FS patients and US healthy controls against SGLL antigens by ELISA. 
The index values of both groups demonstrate higher index values in the FS group.  B. Spearman’s correlation analysis between the 
IgG4 anti-SGLL response in the FS group and the IgE anti-SGLL response in the same donors (lower panel) and the IgG4 anti-Dsg1 
response (upper panel). Both responses show correlations of r=0.58, p<0.0001 (IgG4/IgE anti-SGLL system) and r=0.56, p<0.0001 
(IgG4 anti SGLL/IgG4 anti-hrDsg1 system). 
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3.3.2.   The cross-reactivity of anti-Dsg1 antibodies to SGLL 
 To determine whether the anti-SGLL activity from FS sera is due to the cross-
reactivity of anti-Dsg1 autoantibodies, ELISA was performed with two scFv IgG4 
monoclonal anti-Dsg1 antibodies derived from two FS patients [9] against SGLL antigens.  
As shown in Fig. 2A, both scFv recognize SGLL. To confirm the cross-reactivity of the two 
monoclonal anti-Dsg1 autoantibodies with anti-SGLL antibodies, a competition ELISA assay 
was employed using human recombinant Dsg1 as an inhibitor of the binding of anti-SGLL 
antibodies to immobilized SGLL antigen.  As shown in Fig. 2B, binding of both monoclonal 
antibodies to SGLL are inhibited in a dose dependent manner by soluble Dsg1. These 
Figure 1. FS patients have high levels of anti-SGLL IgG4 antibodies. A) Boxplot analysis of the 
IgG4 response in FS patients (n=45) and UNC healthy controls (n=43) against SGLL antigens by 
ELISA. The index values are higher in the FS group than the HC-UNC group. B) Pearson 
correlation analysis between the IgG4 anti-SGLL and the IgG4 anti-Dsg1 responses in the same 
donors of the FS g up. 
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findings suggest that the anti-SGLL antibody activity in FS patients is, at least in part, due to 
cross-reactivity of the anti-Dsg1 autoantibodies.   
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Fig 2. The cross-reactivity of two IgG4 anti-Dsg1 monoclonal antibodies from FS to SGLL. A. ELISA result shows that both IgG4 anti-
Dsg1 monoclonal antibodies (scFv 5G4 and scFv 2D11) react to SGLL.  B. The binding of both monoclonal antibodies, 2D11 (left panel) 
and 5G4 (right panel) to SGLL is inhibited by hrDsg1 in a concentration dependent manner. 
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3.3.3. The LJM11 major immunogenic component of SGLL is recognized by FS sera 
and IgG4 monoclonal anti-Dsg1 antibodies 
 A large number of secreted proteins are present in Lutzomyia longipalpis saliva [7, 8, 
13] and, LJM11 and LJM17 are the two main antigens that incite antibody responses in 
humans.  Other salivary antigens such as the LJL143 are weakly recognized by humans [13]. 
Figure 2. The cross-reactivity of two IgG4 anti-Dsg1 monoclonal antibodies from FS to SGLL 
by ELISA. A). Both IgG4 anti-Dsg1 monoclonal antibodies (scFv 4E4 and scFv 2D11) react to 
SGLL.  (B). The binding of both monoclonal antibodies: 2D11 (left panel) and 4E4 (right panel) 
to SGLL is inhibited by Dsg1 in a concentration dependent manner. These results were repeated 
three times with similar results. 
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These three recombinant proteins were chosen to determine whether they are recognized by 
IgG4 antibodies from FS patients and normal controls from either FS endemic regions (HC-
endemic) or from non-FS endemic region (HC-UNC).  Ten serum samples from each group 
were randomly selected and tested.  As shown in Fig. 3A, we found that the reactivity of FS 
sera was consistently much stronger to LJM11 than to LJM17 and LJL143.  In addition, the 
level of anti-LJM11 antibodies from FS is significantly higher than healthy donors from HC-
endemic (t-test, p=0.00029) and HC-UNC (t-test, p=0.00013). These results show that IgG4 
antibodies from FS sera chiefly recognize the LJM11 component of SGLL.   
We next tested the reactivity of 4E4 and 2D11 IgG4 anti-Dsg1 monoclonal antibodies 
against LJM11, LJM17 and LJL143.  As shown in Fig. 3B, both monoclonal antibodies bind 
strongly to LJM11, but weakly to LJM17 and LJL143. These findings are similar to those 
observed when testing FS sera.  To further confirm that these two monoclonal antibodies 
cross-react to LJM11, an ELISA inhibition assay was conducted.  A dose of 100µg/ml of 
recombinant Dsg1 incubated with these antibodies was able to inhibit 90% and 70% of the 
bindings of 4E4 and 2D11 to LJM11 respectively (Fig. 3C).  In addition, IP using 
monoclonal antibody 4E4, and FS patient serum show that both react strongly to LJM11 
(~43kD), but weakly to LJM17 (~45kD) and LJL143 (~34kD) (Fig. 4A). These findings 
suggest that LJM11 is the main component of SGLL that triggers the IgG4 immune response 
in humans that cross-react with Dsg1 autoantigen.  
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Fig 3. IgG4 antibodies from FS patients and two IgG4 monoclonal anti-Dsg1 antibodies from FS recognize LJM11, a protein component 
from SGLL. A. Ten random-selected sera from FS (top panel), HC-endemic (middle panel) and HC-US (bottom panel) were tested by 
ELISA for their reactivity to three main SGLL proteins, LJM11, LJM17, and LJL143. The majority of FS sera recognize LJM11 and to a 
lesser degree to JLM17 and LJL143. There were two sera from the HC-endemic group that also recognize these salivary antigens above 
background binding produced by the HC-US.  B. Two monoclonal anti-Dsg1 antibodies derived from FS patients also recognize the 
LJM11 component from SGLL.  C. The binding of both anti-Dsg1 monoclonal antibodies to LJM11 is inhibited by hrDsg1 protein. 
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3.3.4.  The binding of anti-Dsg1 monoclonal antibodies to LJM11 is conformational and 
Ca2+ dependent.   
 Both 4E4 and 2D11 anti-Dsg1 monoclonal antibody failed to react with denatured 
LJM11, LJM17, and LJL143 by Western blot analysis (data not shown), suggesting that 4E4 
Figure 3.  IgG4 antibodies from FS patients and two IgG4 monoclonal anti-Dsg1 antibodies 
derived from FS patients recognize LJM11, a protein component from SGLL. A) The reactivity 
of ten random-selected FS sera (top panel), is higher than donors from the HC-endemic (middle 
panel) and HC-UNC donors (bottom panel) when tested by ELISA with three SGLL main 
proteins, LJM11, LJM17, and LJL143. The reactivity is mainly with the LJM11 protein.  The 
difference between HC-endemic and HC-UNC by the student-t test is not significant (p=0.3800). 
B) The 4E4 and 2D11 IgG4 monoclonal anti-Dsg1 antibodies also recognize the LJM11 
component from SGLL. C) The binding of both anti-Dsg1 monoclonal antibodies to LJM11 is 
inhibited by Dsg1 protein.  
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antibody binding to the SGLL is conformational. Since binding of pathogenic autoantibodies 
to Dsg1 is conformational and Ca2+ dependent [15], we tested the reactivity of these two 
antibodies to LJM11 in the presence of either Ca2+ or EDTA.  As shown in Fig. 4B the 
binding of these monoclonal antibodies from FS patients to LJM11 is also Ca2+-dependent.  
These results suggest that the epitopes recognized by FS sera on SGLL, like those on Dsg1, 
are Ca2+ dependent and conformational.   
 
3.3.5   Mice immunized with LJM11 produce anti-Dsg1 antibodies 
 If SGLL proteins introduced by sand fly bites induce antibodies that cross-react to 
both human Dsg1 and LJM11 in humans, it is expected that mice immunize with LJM11 also 
generate cross-reactive antibodies to human Dsg1.  Anti-Dsg1 reactivity of the sera from 
these mice and control mouse were test by ELISA.  As shown in Fig. 4C (top panel), sera 
from all three mice immunized with LJM11 strongly react to human Dsg1.  The Dsg1 
reactivity of these mouse sera was also tested by IP.  As shown in Fig. 4C (bottom panel), 
the serum from a mouse immunized with LJM11 antigen also immunoprecipitates human 
Dsg1.  Control serum and sera from mice immunized with LJM17 and LJL143 antigens do 
not show reactivity.  These findings further confirm that LJM11 is the major component in 
SGLL that induces the cross-reactive antibodies in both human FS patients and experimental 
mice. 
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Fig 4. Antibodies from FS patients recognize LJM11 and LJM11 immunized mice produce anti-Dsg1 antibodies.  A. Anti-Dsg1 monoclonal 
antibody 5G4 (upper bands) and control (without 5G4) (left panel), sera from a FS patient and a HC control (right panel), were tested by IP 
against three SGLL antigens (LJM11, LJM17 and LJL143). The Western Blot was probed by anti-His-HRP. B. The reaction of two 
monoclonal anti-Dsg1 antibodies with LJM11 by ELISA in the presence of 5mM Ca2+ (black columns) are significantly inhibited in the 
presence of 5mM EDTA (white columns). C. Sera from mice immunized with LJM11 show strong reactivity to hrDsg1 compared to those 
from LJM17 and LJL143 immunized, and control mice (upper panel). Serum from LJM11 immunized mouse, but not from LJM17 and 
LJL143 immunized or control mice, immunoprecipitates human recombinant Dsg1 (lower panel).  IP was conducted using sera from mice 
immunized with LJM11, LJM17, LJL143, and unimmunized mice (Ctrl). The Western Blot was probed by anti-His-HRP. 
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Figure 4.  FS autoantibodies recognize LJM11 and sera from mice immunized with LJM11 bind 
human Dsg1. A)The 4E4 anti-Dsg1 monoclonal antibody (lanes 1,2,3), and control samples without 
4E4 (lanes 4,5,6) (left panel), HC-UNC (lanes 7,8,9) and FS serum (lanes 10, 11, 12) (right panel) 
were tested by IP against LJM11, LJM17 and LJL143 antigens.  The LJM11 heavy band is 
precipitated by 4E4 anti-Dsg1 monoclonal antibody and FS serum. B) The reactions of 4E4 and 
2D11 anti-Dsg1 monoclonal antibodies with LJM11 by ELISA in the presence of 5mM Ca2+ (black 
columns) are significantly inhibited in the presence of 5mM EDTA (white columns). C) Three sera 
from mice immunized with LJM11, show strong reactivity to human Dsg1 by ELISA as compared 
with sera from mice immunized with LJM17 and LJL143 and control mice. The bottom panel shows 
human Dsg1 (lane 1), a control murine serum (lane 2), mouse anti-LJM1 (lane 3), mouse anti-
LJM17 (lane 4) and mouse anti-LJL143 (lane 5) tested against human Dsg1 by IP.    The only serum 
that immunoprecipitates hDsg1 is from mouse anti-LJM11. 
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3.4.   DISCUSSION 
 It is unusual that a population of antibodies would develop cross-reactivity to two 
evolutionarily distant molecules, the human Dsg1 and a sand fly salivary gland component. 
There is no amino acid sequence similarity between Dsg1 and LJM11 (data not shown). The 
Ca2+-dependent interaction suggests that autoantibodies react with both molecules via 
conformational, but not linear, epitopes.  This could explain how two evolutionary distant 
molecules can both be recognized by cross-reactive antibodies since conformational epitopes 
of both molecules may be the same even though their linear structures do not show 
significant homology.  
 Our findings are also in line with molecular mimicry as the mechanism for how 
environmental factors induce autoimmune diseases [1, 16].   Unlike infectious agents that 
induce robust IgG immune response, the low dose of the antigens and the route of the 
exposure (skin) introduced by insect bites predictably induces an IgE response [17].  It is 
known that endemic regions of FS in Brazil are heavily infested of sand flies, and individuals 
living in these areas are constantly exposed to these pests.  It is likely that these individuals 
mount IgE and IgG4 responses to salivary antigens such as the LJM11 protein.  Similar 
antibody responses have been described in people undergoing constant bee stings or during 
immunotherapy of allergic patients [18-21].  It would be expected that those genetically 
predisposed individuals [22] living in endemic areas of FS are constantly exposed to sand fly 
bites (and be sensitized to salivary antigens, including the LJM11 protein), thus generating 
IgG4 anti-SGLL antibodies which, as shown in this investigation, may cross-react with 
unique epitopes on the ectodomain of human Dsg1.  Epitope spreading, as previously 
reported [23], may be the underlying mechanism that leads to the generation of a more 
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diverse autoantibody response in FS.  The cross-reactive antibodies may comprise a complex 
population of non-pathogenic and perhaps pathogenic antibodies.  In this context, it would be 
feasible that certain FS IgG4 autoantibodies may exhibit distinct epitope specificity with 
those IgG4 anti-SGLL antibodies that cross-react with human Dsg1.  It is clear however, that 
testing the pathogenicity of these cross-reactive antibodies is open for further investigations. 
 In summary, this investigation provides the first direct evidence that a non-infectious 
environmental agent may play a significant role in the initiation of an autoimmune disease 
via molecular mimicry.   
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CHAPTER IV 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 
4.1. SUMMARY 
 
 Traditionally, IgG4 has been considered to have a protective and anti-inflammatory 
function; however, recent studies demonstrate that this immunoglobulin can also induce 
disease [1, 2]. A restricted IgG4 immune response in humans has been reported in patients 
with parasitosis [3], autoimmune pancreatitis [4], as well as bee handlers [5], allergic 
individuals during desensitization therapy [6], and the recently reported IgG4-related disease 
[7, 8]. Pemphigus is not the exception for such IgG4 restriction, but information about its 
pathogenic role in skin disease is limited [9]. 
  A predominantly IgG4 autoantibody response has been reported in patients with 
active endemic pemphigus foliaceus (FS) living in LV, Brazil. Moreover, FS IgG4 anti-
epidermal antibodies are known to be pathogenic [10] and monovalent Fab fragments are 
sufficient to induce blistering in the mouse model of FS [11]. Thus, the pathogenicity of 
these autoantibodies is independent from their Fc portion [12]. Association with certain 
HLA-DR alleles in IgG4-mediated diseases such as autoimmune pancreatitis and myasthenia 
gravis has been reported [13, 14] and the alleles for FS susceptibility have been identified in 
the HLA-DRB1 gene [15]. This indicates a genetic predisposition to develop autoimmune 
diseases that are IgG4-restricted. 
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 FS is a good model to study the progression of autoimmune disease. The 
epidemiology of FS and the fact that healthy individuals in the preclinical stage also possess 
antibodies against the autoantigen makes it possible to explore every step of disease 
development. The titers of anti-Dsg1 autoantibodies are directly related to the severity and 
activity of disease, and the B cell repertoire in FS is antigen driven during preclinical stage 
[16]. Subclass switching has been suggested to occur in FS, where an initial mixture of IgG1 
and IgG4 response is observed in healthy individuals and overtime, a dramatic rise in IgG4 
anti-Dsg1 autoantibodies coincides with the onset of active disease [17]. In addition, IgG4 
anti-Dsg1 autoantibodies are very sensitive predictors of disease in FS [18], which points to 
the IgG4 response as a key step in the development of FS. 
 The prevalence of FS is determined by proximity to an endemic area, suggesting that 
environmental risks factors are potential triggers of the anti-Dsg1 autoimmune response 
observed in these patients. As described in Chapter 1, hDsg1 has five calcium- binding 
cadherin repeats (EC1 to EC5) in its extracellular domain, with EC5 being proximal to the 
cell membrane. A previous study showed that the total IgG response against Dsg1 evolves 
from a non-pathogenic response targeting the EC5 domain in healthy individuals (no skin 
lesions) to a pathogenic response against the EC1-EC2 ectodomains of Dsg1 in FS patients. 
Additionally, the response shifted back to EC5 upon remission [19]. These findings 
demonstrate that the autoimmune response against Dsg1 is dynamic and that EC1 and EC2 
domains of Dsg1 are relevant to FS acantholysis. 
 It is possible that the dominant epitope in Dsg1 recognized by FS autoantibodies 
exhibits molecular mimicry with an environmental trigger. Also, it appears that the epitopes 
for IgG1 and IgG4 are different because of the different outcomes observed when each 
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subclass is predominant. Therefore, identification of specific epitopes in Dsg1 for pathogenic 
and non-pathogenic FS autoantibodies and their association with an environmental trigger 
will be a key step in our efforts to understand the pathogenesis of FS (Fig. 1). 
 
 
 
 
 
  
Figure 1. A working model for FS immunopathogenesis. An “unknown” environmental 
trigger induces the production of autoantibodies against EC5 domain, these antibodies are 
of the IgG1 and IgG4 subclasses. Overtime, a pathogenic autoimmune response against 
EC1 and/or EC2 is generated, and this response is restricted to IgG4. 
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 Previous epitope mapping studies using domain-swapped molecules suggested that 
the N-terminal end of Dsg1 is the target for potentially pathogenic FS autoantibodies. These 
studies were only able to identify regions at least 100 residues long using a mix of IgG 
autoantibodies, leaving unknown the exact sequence recognized by FS autoantibodies 
relevant to disease. In this dissertation, I have identified the amino acid sequences for two 
dominant epitopes (16 and 13 residues long) in Dsg1 that are recognized by pathogenic IgG4 
autoantibodies purified from FS patients sera. Moreover, these 2 epitopes are conformational 
and are located within EC1 and EC2 domains respectively. Additionally, 2 residues (M133 
and Q135) in the EC1 epitope are shown to be required for the conformation of this epitope 
and therefore for the binding of the pathogenic FS IgG4 autoantibodies.  The EC1 epitope 
overlaps both the homophilic adhesive interface of the molecule defined by amino acid 
residues in positions 51(W51) and 130 (A130) and the cell-adhesion recognition site motif 
RAL, strongly supporting the steric hindrance model of FS pathogenesis and suggesting that 
the specific binding of IgG4 autoantibodies to this epitope disrupts the homophilic adhesion 
of Dsg1 leading to acantholysis. 
 A case-control epidemiological study suggests that certain living conditions and 
exposure to hematophagus insect bites are risk factors for FS [20]. Three insects are 
suspected to be involved: Lutzomyia longipalpis (sand flies), reduviids (kissing bugs) and 
simuliids (black flies).  These insects are vectors of leishmaniasis, Chagas disease and 
onchocerciasis, respectively. Chapter 3 of this dissertation showed a novel cross-reactive 
antigen present in the saliva of a hematophagus insect (Lutzomya longipalpis) that is 
recognized by IgG4 antibodies from FS patients. The binding to this cross-reactive antigen 
(LJM11) is also calcium-dependent, and the absence of significant homology between 
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LJM11 and hDsg1 structures suggests that the epitopes recognized in both molecules are 
conformational.  
 Much work remains to fully elucidate the etiology and immune pathogenesis of FS. 
The findings of this dissertation advance our understanding FS acantholysis, by providing 
supportive evidence for the concepts of steric hindrance and molecular mimicry as 
mechanisms inducers of FS autoimmunity. 
 
4.2. FUTURE DIRECTIONS 
 
 The data presented in this dissertation refines the understanding of key factors that 
contribute to the development of FS. However, it also opens many questions for future 
research. 
 The pathogenicity of IgG4 FS antibodies has been confirmed and the presence of 
IgG1 anti-Dsg1 autoantibodies seems to be irrelevant to active disease. However, it has been 
suggested that the initial immune response in FS is IgG1-mediated but doesn’t induce 
blistering. Identification of the hDsg1 epitopes recognized by IgG1 and assessment of the 
structural similarities of hDsg1 epitopes and potential environmental triggers in future studies 
may help elucidate the mechanisms for the initial non-pathogenic FS autoimmune response.  
 More than one environmental factor appears to be involved in FS pathogenesis. It has 
been suggested that proteins in the saliva of black flies cross-react with the EC5 domain of 
hDsg1, which may be the trigger for the initial response and is perhaps driven by IgG1 anti-
Dsg1 antibodies. The cross-reactivity of IgG4 antibodies with a salivary protein reported in 
this dissertation also suggests that there may be a second environmental trigger that induces 
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epitope spreading and therefore a pathogenic response. These observations need to be further 
investigated in order to dissect the functions of both subclasses in FS pathogenesis. 
 The epitope identified in EC2 seems to not be recognized by majority of IgG4 
antibodies. However it is common across FS patients and its pathogenicity has not been ruled 
out.  The relevance of this and the other minor epitopes needs to be explored and perhaps will 
gives us more insight in the epitope spreading cascade especially in the early stages of the 
disease. 
 A crystal 3D structure of hDsg1 is urgently needed to help identify the different 
conformations that display the epitopes in Dsg1. This information will enable researchers to 
match the Dsg1 epitopes with the potential epitopes found in the sequence of salivary 
proteins from insects (such as LJM11).  These data will provide a clearer picture of how an 
environmental trigger induces disease, and perhaps will provide insight into the sequencial 
epitope spreading events in FS. 
 While there is evidence that anti-Dsg1 autoantibodies might simply disrupt adhesive 
Dsg1 dimers, others have suggested that antibody binding could initiate signaling events that 
drive the disassembly of desmosomes to reduce intercellular adhesion [21, 22]. My epitope 
mapping studies support the notion of direct disruption of adhesion. However, it would be 
interesting to investigate if whether IgG1 or IgG4 is the responsible for activation of 
signaling transduction or apoptosis upon binding to Dsg1.  
 Finally, research into the involvement of non-desmosomal components of 
intercellular junctions may provide more answers to the questions that surround FS etiology 
and pathogenesis.  For example, early EM-based studies have shown that upon binding of 
pemphigus autoantibodies to the epidermal cell surface, the first structural change observed 
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was widening of the intercellular spaces between desmosomes where E-cadherin mediates 
cell adhesion.  Only later did desmosomes begin to split in two halves with subsequent 
complete cell separation [23]. I have previously reported that anti-E-cadherin autoantibodies 
are detected in the serum of pemphigus patients [24], which suggests that pemphigus 
autoantibodies target the ectodomain of adhesion molecules in both desmosomes and 
adherens junctions, thus, dysfunction of adhesion mediated by both types of molecules may 
contribute to the pemphigus epidermal injury. 
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